<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">41913</article-id><article-id pub-id-type="doi">10.7554/eLife.41913</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title><italic>GREB1</italic> amplifies androgen receptor output in human prostate cancer and contributes to antiandrogen resistance</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-122489"><name><surname>Lee</surname><given-names>Eugine</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-86467"><name><surname>Wongvipat</surname><given-names>John</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-122490"><name><surname>Choi</surname><given-names>Danielle</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-40377"><name><surname>Wang</surname><given-names>Ping</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-127642"><name><surname>Lee</surname><given-names>Young Sun</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-40378"><name><surname>Zheng</surname><given-names>Deyou</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-4354-5337</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-3586"><name><surname>Watson</surname><given-names>Philip A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-122491"><name><surname>Gopalan</surname><given-names>Anuradha</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-1025"><name><surname>Sawyers</surname><given-names>Charles L</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-4955-6475</contrib-id><email>sawyersc@mskcc.org</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund10"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf3"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Human Oncology and Pathogenesis Program</institution><institution>Memorial Sloan Kettering Cancer Center</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Department of Genetics</institution><institution>Albert Einstein College of Medicine</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution content-type="dept">Department of Neurology</institution><institution>Albert Einstein College of Medicine</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution content-type="dept">Department of Pathology</institution><institution>Memorial Sloan Kettering Cancer Center</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution>Howard Hughes Medical Institute</institution><addr-line><named-content content-type="city">Chevy Chase</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution content-type="dept">Department of Neuroscience</institution><institution>Albert Einstein College of Medicine</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Tannock</surname><given-names>Ian</given-names></name><role>Reviewing Editor</role><aff><institution>Princess Margaret Cancer Centre</institution><country>Canada</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Morrison</surname><given-names>Sean J</given-names></name><role>Senior Editor</role><aff><institution>Howard Hughes Medical Institute, University of Texas Southwestern Medical Center</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>15</day><month>01</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>8</volume><elocation-id>e41913</elocation-id><history><date date-type="received" iso-8601-date="2018-09-11"><day>11</day><month>09</month><year>2018</year></date><date date-type="accepted" iso-8601-date="2018-12-27"><day>27</day><month>12</month><year>2018</year></date></history><permissions><copyright-statement>© 2019, Lee et al</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Lee et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-41913-v2.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.41913.001</object-id><p>Genomic amplification of the androgen receptor (<italic>AR</italic>) is an established mechanism of antiandrogen resistance in prostate cancer. Here, we show that the magnitude of <italic>AR</italic> signaling output, independent of <italic>AR</italic> genomic alteration or expression level, also contributes to antiandrogen resistance, through upregulation of the coactivator <italic>GREB1</italic>. We demonstrate 100-fold heterogeneity in <italic>AR</italic> output within human prostate cancer cell lines and show that cells with high <italic>AR</italic> output have reduced sensitivity to enzalutamide. Through transcriptomic and shRNA knockdown studies, together with analysis of clinical datasets, we identify <italic>GREB1</italic> as a gene responsible for high <italic>AR</italic> output. We show that <italic>GREB1</italic> is an <italic>AR</italic> target gene that amplifies <italic>AR</italic> output by enhancing <italic>AR</italic> DNA binding and promoting <italic>EP300</italic> recruitment. <italic>GREB1</italic> knockdown in high <italic>AR</italic> output cells restores enzalutamide sensitivity <italic>in vivo</italic>. Thus, <italic>GREB1</italic> is a candidate driver of enzalutamide resistance through a novel feed forward mechanism.</p></abstract><abstract abstract-type="executive-summary"><object-id pub-id-type="doi">10.7554/eLife.41913.002</object-id><title>eLife digest</title><p>The prostate is a roughly walnut-sized gland that makes up part of the reproductive system in men. The normal development of this gland depends on a protein known as the androgen receptor. This protein also plays an important role in driving the growth of prostate cancers, and doctors routinely treat such cancers with drugs that block the androgen receptor. While these treatments often shrink the tumors at first, the prostate cancer cells commonly become resistant to the existing “antiandrogen” drugs, highlighting the need to find new drugs for this cancer.</p><p>The main way that prostate cancers become resistant to antiandrogen drugs is by making more of the androgen receptor. As such, a better understanding of this protein’s activity may prove vital to discovering new treatments. Together with other proteins called co-factors, the androgen receptor binds to DNA and switches on a set of target genes that drive the growth of prostate cancers. The activity of these genes, referred to as “androgen receptor output”, varies between different patients with prostate cancer and even between different cells from a single patient’s tumor. This variation may occur even when the level of the androgen receptor is constant, which suggests that other factors affect the output of the androgen receptor.</p><p>Lee et al. set out to discover if cells with different androgen receptor outputs, but constant androgen receptor levels, respond differently to antiandrogen drugs. First, human prostate cancer cells were separated according to their androgen receptor output. Lee et al. then treated all the cells with an antiandrogen drug known as enzalutamide: tumors grown from cells with a high output became resistant to the drug faster than cells with low output. Next, a large-scale experiment revealed the differences in gene activity between cells with high and low outputs. On average, the cells with a high androgen receptor output had more of an androgen receptor co-factor called GREB1 than the cells with a low output. Biochemical experiments showed that the GREB1 protein interacts with the androgen receptor and amplifies the expression of the receptor’s target genes. When the levels of the GREB1 protein were experimentally decreased in prostate cancer cells with a high androgen receptor output, the cells became less resistant to the antiandrogen drug.</p><p>Future work will be needed to know if GREB1 levels are a good proxy for patients with high androgen receptor output. The current work predicts that those patients will respond less well to current antiandrogen drugs. A better understanding of how GREB1 and androgen receptor cooperate may also be useful for developing new drugs to treat prostate cancer.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>intra-tumoral heterogeneity</kwd><kwd>AR signaling output</kwd><kwd>AR coactivator</kwd><kwd>enzalutamide</kwd><kwd>GREB1</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000005</institution-id><institution>U.S. Department of Defense</institution></institution-wrap></funding-source><award-id>W81XWH-15-1-0540</award-id><principal-award-recipient><name><surname>Lee</surname><given-names>Eugine</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution>Iris and Junming Le Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Lee</surname><given-names>Eugine</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000011</institution-id><institution>Howard Hughes Medical Institute</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Sawyers</surname><given-names>Charles L</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>CA155169</award-id><principal-award-recipient><name><surname>Sawyers</surname><given-names>Charles L</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009784</institution-id><institution>Starr Foundation</institution></institution-wrap></funding-source><award-id>I10-0062</award-id><principal-award-recipient><name><surname>Sawyers</surname><given-names>Charles L</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>CA193837</award-id><principal-award-recipient><name><surname>Sawyers</surname><given-names>Charles L</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>CA224079</award-id><principal-award-recipient><name><surname>Sawyers</surname><given-names>Charles L</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>CA092629</award-id><principal-award-recipient><name><surname>Sawyers</surname><given-names>Charles L</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>CA160001</award-id><principal-award-recipient><name><surname>Sawyers</surname><given-names>Charles L</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>CA008748</award-id><principal-award-recipient><name><surname>Sawyers</surname><given-names>Charles L</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Prostate cancer cells maintain heterogeneous androgen receptor transcriptional activity through upregulation of AR-regulated coactivator GREB1, and cells with high activity rapidly develop resistance to antiandrogen therapy in a GREB1-dependent manner.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Androgen receptor (<italic>AR</italic>) targeted therapy is highly effective in advanced prostate cancer but is complicated by the emergence of drug resistance, called castration-resistant prostate cancer (CRPC) (<xref ref-type="bibr" rid="bib33">Shen and Abate-Shen, 2010</xref>; <xref ref-type="bibr" rid="bib41">Watson et al., 2015</xref>). The most common mechanism of CRPC is restored <italic>AR</italic> signaling, primarily through amplification of <italic>AR</italic> (<xref ref-type="bibr" rid="bib10">Chen et al., 2004</xref>; <xref ref-type="bibr" rid="bib29">Robinson et al., 2015</xref>). The importance of <italic>AR</italic> amplification as a clinically important drug resistance mechanism is underscored by recent data showing that <italic>AR</italic> amplification, detected in circulating tumor DNA or in circulating tumor cells (CTCs), is correlated with reduced clinical benefit from the next generation <italic>AR</italic> inhibitors abiraterone or enzalutamide (<xref ref-type="bibr" rid="bib2">Annala et al., 2018</xref>; <xref ref-type="bibr" rid="bib25">Podolak et al., 2017</xref>).</p><p>Genomic landscape studies of prostate cancer have revealed several molecular subtypes defined by distinct genomic drivers (<xref ref-type="bibr" rid="bib5">Berger et al., 2011</xref>; <xref ref-type="bibr" rid="bib8">Cancer Genome Atlas Research Network, 2015</xref>; <xref ref-type="bibr" rid="bib36">Taylor et al., 2010</xref>). In addition to this genomic heterogeneity, primary prostate cancers also display heterogeneity in <italic>AR</italic> transcriptional output, measured by an <italic>AR</italic> activity score (<xref ref-type="bibr" rid="bib18">Hieronymus et al., 2006</xref>). Notably, these differences in transcriptional output occur in the absence of genomic alterations in <italic>AR</italic>, which are generally found only in CRPC (<xref ref-type="bibr" rid="bib8">Cancer Genome Atlas Research Network, 2015</xref>). One potential explanation for this heterogeneity in <italic>AR</italic> transcriptional output is through coactivators and other <italic>AR</italic> regulatory proteins such as <italic>FOXA1</italic>, <italic>SPOP</italic>, <italic>FOXP1</italic> and <italic>TRIM24</italic> (<xref ref-type="bibr" rid="bib8">Cancer Genome Atlas Research Network, 2015</xref>; <xref ref-type="bibr" rid="bib16">Geng et al., 2013</xref>; <xref ref-type="bibr" rid="bib17">Groner et al., 2016</xref>; <xref ref-type="bibr" rid="bib26">Pomerantz et al., 2015</xref>; <xref ref-type="bibr" rid="bib35">Takayama et al., 2014</xref>).</p><p>Much of the work to date has focused on inter-tumoral heterogeneity. Here, we address the topic of intra-tumoral heterogeneity in <italic>AR</italic> transcriptional output, for which we find substantial evidence in prostate cancer cell lines and in primary prostate tumors. Using a sensitive reporter of <italic>AR</italic> transcriptional activity to isolate cells with low versus high <italic>AR</italic> output, we show that high <italic>AR</italic> output cells have an enhanced response to low doses of androgen and reduced sensitivity to enzalutamide, in the absence of changes in <italic>AR</italic> mRNA and protein expression. To understand the molecular basis for these differences, we performed transcriptome and shRNA knockdown studies and identified three genes (<italic>GREB1</italic>, <italic>KLF8</italic> and <italic>GHRHR</italic>) upregulated in high <italic>AR</italic> output cells, all of which promote <italic>AR</italic> transcriptional activity through a feed-forward mechanism. Of these, we prioritized <italic>GREB1</italic> for further characterization because <italic>GREB1</italic> mRNA levels are increased in primary prostate tumors that have high <italic>AR</italic> activity. <italic>GREB1</italic> amplifies <italic>AR</italic> transcriptional activity through a two-part mechanism: by promoting <italic>EP300</italic> recruitment and by enhancing <italic>AR</italic> binding to chromatin. Importantly, <italic>GREB1</italic> knockdown converted high <italic>AR</italic> output cells to a low <italic>AR</italic> output state and restored enzalutamide sensitivity <italic>in vivo</italic>. Collectively, these data implicate <italic>GREB1</italic> as an <italic>AR</italic> signal amplifier that contributes to prostate cancer disease progression and antiandrogen resistance.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Isolation of cells with low and high <italic>AR</italic> output but comparable <italic>AR</italic> expression</title><p>Previous work using a <italic>KLK3</italic> promoter/GFP reporter (PSAP-eGFP) showed that LNCaP prostate cancer cells display varying levels of eGFP expression. Characterization of low GFP cells in this analysis revealed reduced <italic>AR</italic> levels and increased expression of stem cell and developmental gene sets (<xref ref-type="bibr" rid="bib27">Qin et al., 2012</xref>). We explored this question in the context of the contemporary data on heterogeneity in <italic>AR</italic> transcriptional output using a different <italic>AR</italic>-responsive reporter, ARR<sub>3</sub>tk-eGFP, where eGFP expression is driven by the probasin promoter modified to contain three <italic>AR </italic>responsive elements (<xref ref-type="bibr" rid="bib34">Snoek et al., 1998</xref>). LNCaP (<xref ref-type="fig" rid="fig1">Figure 1</xref>) and CWR22PC-EP (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>) prostate cancer cells containing a single copy of the reporter construct were derived by infection with lentivirus containing the reporter at a low multiplicity of infection (MOI) (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Remarkably, we observed &gt;100 fold range in eGFP expression, as measured by flow cytometry, despite similar levels of <italic>AR</italic> by immunofluorescence microscopy (<xref ref-type="fig" rid="fig1">Figure 1B,C</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>).</p><fig-group><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.41913.003</object-id><label>Figure 1.</label><caption><title>Characterization of prostate cancer cells with low vs. high <italic>AR</italic> output.</title><p>(<bold>A</bold>) The LNCaP and CWR22Pc-EP reporter cell lines were generated by lentiviral infection with the eGFP <italic>AR</italic> reporter construct (details can be found in Materials and methods). Cells with stable integration of the construct were positively sorted by mCherry expression using flow cytometry. (<bold>B</bold>) LNCaP cells infected with the <italic>AR</italic> reporter display variable expression levels of eGFP (green) and AR (magenta). Nuclei were labeled with DAPI (blue). (<bold>C</bold>) LNCaP cells with low (ARsig-lo) or high (ARsig-hi) <italic>AR</italic> activities were sorted using flow cytometry based on eGFP <italic>AR</italic>-reporter expression. (<bold>D–E</bold>) LNCaP ARsig-hi cells have higher <italic>AR</italic> output while having the same level of <italic>AR</italic>. The q-PCR data (<bold>D</bold>) is presented as mean fold change ±SD relative to the bulk population. NS = not significant, ****p&lt;0.0001, one-way ANOVA compared to the bulk population. (<bold>F</bold>) Gene set enrichment analysis (GSEA) shows that the gene sets up- and down-regulated by androgen are enriched in LNCaP ARsig-hi and ARsig-lo cells, respectively. (<bold>G</bold>) LNCaP ARsig-lo and ARsig-hi cells maintain their <italic>AR</italic> activity levels over time. (<bold>H</bold>) LNCaP ARsig-hi cells showed enhanced upregulation of <italic>AR</italic> target genes in response to DHT treatment. The q-PCR data is presented as mean fold change ±SD relative to the DMSO control. NS = not significant, *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001, one-way ANOVA compared to the bulk population. (<bold>I</bold>) LNCaP/AR xenografts derived from ARsig-hi cells become resistant to enzalutamide faster than other populations. The bulk, sorted ARsig-lo and ARsig-hi cells were injected into physically castrated mice and the mice were treated with enzalutamide immediately after injection. Data is presented as mean ±SEM (N = 10). NS = not significant, *p&lt;0.05, one-way ANOVA.</p><p><supplementary-material id="fig1sdata1"><object-id pub-id-type="doi">10.7554/eLife.41913.008</object-id><label>Figure 1—source data 1.</label><caption><title>GSEA Results (ARsig-lo vs. ARsig-hi).</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-41913-fig1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-41913-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.41913.004</object-id><label>Figure 1—figure supplement 1.</label><caption><title>Characterization of CWR22Pc-EP prostate cancer cells with low vs. high <italic>AR</italic> output.</title><p>(<bold>A</bold>) CWR22Pc-EP cells with low (ARsig-lo) or high (ARsig-hi) <italic>AR</italic> activities were sorted using flow cytometry based on eGFP <italic>AR</italic>-reporter expression. (<bold>B–C</bold>) CWR22Pc-EP ARsig-hi cells have higher <italic>AR</italic> output while having the same level of <italic>AR</italic>. The q-PCR data (<bold>B</bold>) is presented as mean fold change ±SD relative to the bulk population. NS = not significant, *p&lt;0.05, ****p&lt;0.0001, one-way ANOVA compared to the bulk population. (<bold>D</bold>) CWR22Pc-EP ARsig-lo and ARsig-hi cells maintain their <italic>AR</italic> activity levels over time. (<bold>E</bold>) CWR22Pc-EP ARsig-hi cells have enhanced DHT-induced <italic>AR</italic> transcriptional activity compared to ARsig-lo cells. The q-PCR data is presented as mean fold change ±SD relative to the DMSO control. NS = not significant, *p&lt;0.05, unpaired t-test compared to ARsig-lo population.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-41913-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.41913.005</object-id><label>Figure 1—figure supplement 2.</label><caption><title>LNCaP ARsig-lo and ARsig-hi cells have comparable nuclear AR levels.</title><p>The BRD4 and tubulin were used as nuclear and cytoplasmic loading controls, respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-41913-fig1-figsupp2-v2.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.41913.006</object-id><label>Figure 1—figure supplement 3.</label><caption><title>Characterization of LNCaP/AR prostate cancer cells with low vs. high <italic>AR</italic> output.</title><p>(<bold>A–C</bold>) LNCaP/AR cells with low (ARsig-lo) and high (ARsig-hi) <italic>AR</italic> activities were sorted using flow cytometry based on eGFP <italic>AR</italic>-reporter expression. The <italic>AR</italic> reporter activity (<bold>A</bold>) and <italic>AR</italic> target gene expression (<bold>B–C</bold>) were analyzed 7 days post sorting. The q-PCR data (<bold>B</bold>) is presented as mean fold change ±SD relative to the bulk population. NS = not significant, ****p&lt;0.0001, one-way ANOVA compared to the bulk population.</p></caption><graphic mime-subtype="png" mimetype="image" xlink:href="elife-41913-fig1-figsupp3-v2"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.41913.007</object-id><label>Figure 1—figure supplement 4.</label><caption><title>AR and KLK3 staining in untreated localized prostate cancer shows heterogeneous KLK3 staining that is not strictly correlated with AR level.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-41913-fig1-figsupp4-v2.tif"/></fig></fig-group><p>We then used flow cytometry to isolate eGFP-positive cells from both ends of the spectrum of <italic>AR</italic> transcriptional output, which we refer to as ARsig-hi (high <italic>AR</italic> output) and ARsig-lo (low <italic>AR</italic> output) cells, respectively (<xref ref-type="fig" rid="fig1">Figure 1C</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). ARsig-hi cells also express higher levels of endogenous <italic>AR</italic> target genes (<italic>FKBP5</italic>, <italic>KLK3</italic>, <italic>TRPM8</italic>) (<xref ref-type="fig" rid="fig1">Figure 1D,E</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B,C</xref>), and have an overall increase in <italic>AR</italic> transcriptional activity based on RNA-sequencing analysis (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). In addition, the ARsig-lo and ARsig-hi transcriptional phenotypes remain stable for over 30 days post-sorting (<xref ref-type="fig" rid="fig1">Figure 1G</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>). Interestingly, ARsig-lo cells showed upregulation of gene sets related to proliferation and cell cycle (<xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). Of note, <xref ref-type="bibr" rid="bib27">Qin et al. (2012)</xref> reported downregulation of these gene sets in their low/absent <italic>KLK3</italic> cells, suggesting that the two reporters read out different transcriptional activities. Importantly, the difference in <italic>AR</italic> output between ARsig-lo and ARsig-hi cells is not explained by different levels of <italic>AR</italic> expression or nuclear translocation, since both were comparable in each subpopulation (<xref ref-type="fig" rid="fig1">Figure 1D,E</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B,C</xref>, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>).</p><p>We next asked if isolated ARsig-lo and ARsig-hi populations have different responses to ligands such as dihydrotestosterone (DHT) or antagonists such as enzalutamide. ARsig-hi cells showed enhanced sensitivity to DHT in a dose-dependent manner (<xref ref-type="fig" rid="fig1">Figure 1H</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E</xref>). This result is similar to the effect of increased <italic>AR</italic> expression in conferring sensitivity to low doses of androgen (<xref ref-type="bibr" rid="bib10">Chen et al., 2004</xref>), but now without a change in <italic>AR</italic> level. To address sensitivity to enzalutamide, we used LNCaP/AR xenografts (derived from LNCaP cells) because this model has a track record of revealing clinically relevant mechanisms of enzalutamide resistance (<xref ref-type="bibr" rid="bib3">Arora et al., 2013</xref>; <xref ref-type="bibr" rid="bib4">Balbas et al., 2013</xref>). As we did with LNCaP and CWR22PC-EP cells, we derived ARsig-lo and ARsig-hi subpopulations by flow cytometry and also observed differential <italic>AR</italic> output despite similar levels of <italic>AR</italic> expression (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A–C</xref>). Remarkably, ARsig-hi cells developed enzalutamide resistance significantly faster that ARsig-lo or parental cells when injected into castrated mice treated with enzalutamide (<xref ref-type="fig" rid="fig1">Figure 1I</xref>).</p><p>Having demonstrated heterogeneous <italic>AR</italic> output within prostate cancer cell lines, we asked if similar, intra-tumoral heterogeneity is observed clinically by immunohistochemical analysis of <italic>KLK3</italic> and <italic>AR</italic> expression in several primary cancers. Consistent with previous reports (<xref ref-type="bibr" rid="bib27">Qin et al., 2012</xref>; <xref ref-type="bibr" rid="bib31">Ruizeveld de Winter et al., 1994</xref>), we observed heterogeneous <italic>KLK3</italic> staining that is not strictly correlated with <italic>AR</italic> level. For example, we found variable intensity of <italic>KLK3</italic> staining in tumor cells with comparable levels of <italic>AR</italic> staining (lined boxes; <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>) and, conversely, variable intensity of <italic>AR</italic> staining in tumor cells with similar <italic>KLK3</italic> staining (dotted circles; <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>). Although this is a small dataset, the results indicate that the <italic>AR</italic> transcriptional heterogeneity we observe in prostate cancer cell lines is present in patient samples. Emerging technologies for conducting single cell RNA and protein analysis in clinical material will enable deeper investigation of this question.</p></sec><sec id="s2-2"><title>GREB1 maintains high AR transcriptional output</title><p>To elucidate the molecular basis underlying the differences in ARsig-lo and ARsig-hi cells, we performed RNA-sequencing and found 69 genes upregulated in ARsig-lo cells and 191 genes upregulated in ARsig-hi cells (fold change ≥1.5, p&lt;0.05, <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>). In addition to enrichment of gene sets regulated by androgen (<xref ref-type="fig" rid="fig1">Figure 1F</xref>), human prostate luminal and basal cell gene sets were enriched in ARsig-hi and ARsig-lo cells, respectively (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Based on these results, we postulated that high <italic>AR</italic> output could be a consequence of upregulation of transcriptional co-activators and/or of genes involved in luminal differentiation. We therefore filtered the list of 191 genes upregulated in ARsig-hi cells and identified 33 genes annotated as co-activators or luminal genes (<xref ref-type="supplementary-material" rid="fig2sdata2">Figure 2—source data 2</xref>), then measured the consequence of shRNA knockdown of each one on <italic>AR</italic> output in ARsig-hi cells (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Three of the 33 candidate genes (<italic>GREB1</italic>, <italic>GHRHR</italic>, <italic>KLF8</italic>) inhibited <italic>AR</italic> activity when knocked down in ARsig-hi cells, with successful knockdown confirmed by qRT-PCR (<xref ref-type="fig" rid="fig2">Figure 2C,D</xref>). <italic>AR</italic> knockdown served as a positive control, and <italic>ACPP</italic> (one of the 30 genes that did not score) served as a negative control. Interestingly, all three hits are transcriptional upregulated by DHT simulation (<xref ref-type="fig" rid="fig2">Figure 2E</xref>), which likely explains their increased expression in ARsig-hi cells.</p><fig-group><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.41913.009</object-id><label>Figure 2.</label><caption><title>Knockdown of the three <italic>AR</italic> regulated genes, <italic>GREB1</italic>, <italic>GHRHR</italic> and <italic>KLF8</italic>, inhibited <italic>AR</italic> activity in cells with high <italic>AR</italic> activity.</title><p>(<bold>A</bold>) Gene set enrichment analysis (GSEA) shows that genes upregulated in human prostate luminal and basal cells are enriched in LNCaP ARsig-hi and ARsig-lo cells, respectively. (<bold>B</bold>) The schematic of the knockdown study with 33 selected genes upregulated in LNCaP ARsig-hi cells. Details can be found in the Materials and methods. (<bold>C</bold>) The flow cytometry results show that the knockdown of <italic>GREB1</italic>, <italic>GHRHR</italic> and <italic>KLF8</italic> inhibited <italic>AR</italic> reporter activity in LNCaP ARsig-hi cells. Top: The flow cytometry plot of one of the duplicate assays is shown. Bottom: The normalized median fluorescence intensity (MFI) of eGFP reporter in each assay is shown. <italic>AR</italic> shRNA was used as a positive control. <italic>ACPP</italic> shRNA is shown as a representative hairpin that had no effect on reporter activity. (<bold>D</bold>) The knockdown level of <italic>AR</italic>, <italic>GREB1</italic>, <italic>GHRHR</italic>, <italic>KLF8</italic> and <italic>ACPP</italic> from the cells represented in (<bold>C</bold>). The q-PCR data is presented as mean fold change ±SD relative to the shRenilla control. (<bold>E</bold>) The transcription of <italic>GREB1</italic>, <italic>GHRHR</italic> and <italic>KLF8</italic> is regulated by androgen in LNCaP. The data is presented as mean fold change ±SD relative to the DMSO control. NS = not significant, *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001, one-way ANOVA compared to the DMSO control. (<bold>F</bold>) The correlation between RNA levels of <italic>GREB1</italic>, <italic>GHRHR</italic> and <italic>KLF8</italic> and AR score in 333 TCGA primary prostate tumors were analyzed using Pearson’s correlation analysis (<bold>r</bold>). The RNA levels of the three genes were also compared between tumors with lowest (ARsig-lo, red points) and highest (ARsig-hi, blue points) AR score (5% of 333 cases: 17 cases each). NS = not significant, **p&lt;0.01, ****p&lt;0.0001, unpaired t-test. *One data point (<italic>GHRHR</italic>, x = −0.67, y = 1252.6072) is outside the y-axis limit. (<bold>G</bold>) The <italic>GREB1</italic> function is inhibited by CRISPR/Cas9 in four LNCaP ARsig-hi sublines. (Top) <italic>AR</italic> reporter activity was inhibited in all four <italic>GREB1</italic> CRISPR cell lines compared to control (SgNT). (Bottom) An example of the genomic alteration in the targeted sequence for each cell line is shown. (<bold>H</bold>) The CRISPR/Cas9-mediated inhibition of <italic>GREB1</italic> suppressed KLK3 expression without affecting the AR level.</p><p><supplementary-material id="fig2sdata1"><object-id pub-id-type="doi">10.7554/eLife.41913.011</object-id><label>Figure 2—source data 1.</label><caption><title>Differentially expressed genes between ARsig-lo vs. ARsig-hi.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-41913-fig2-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><object-id pub-id-type="doi">10.7554/eLife.41913.012</object-id><label>Figure 2—source data 2.</label><caption><title>Summary of Median eGFP Intensity of small-scale shRNA screen.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-41913-fig2-data2-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2sdata3"><object-id pub-id-type="doi">10.7554/eLife.41913.013</object-id><label>Figure 2—source data 3.</label><caption><title>AR scores and RNA levels of <italic>GREB1</italic>, <italic>GHRHR</italic> and <italic>KLF8</italic> of 333 TCGA cases.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-41913-fig2-data3-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-41913-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.41913.010</object-id><label>Figure 2—figure supplement 1.</label><caption><title>Inhibition of <italic>GREB1</italic> suppresses <italic>AR</italic> transcriptional activity in CWR22Pc-EP cells.</title><p>(<bold>A</bold>) <italic>GREB1</italic> is upregulated in CWR22Pc-EP ARsig-hi cells. *p&lt;0.05, unpaired t-test. (<bold>B</bold>) Knockdown of <italic>GREB1</italic> in CWR22Pc-EP ARsig-hi cells inhibited <italic>AR</italic> reporter activity.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-41913-fig2-figsupp1-v2.tif"/></fig></fig-group><p>Among the three, <italic>GREB1</italic> emerged as the most compelling candidate for further investigation based on interrogation of clinical datasets. Specifically, we found a statistically significant positive correlation (<italic>r</italic>) between <italic>GREB1</italic> RNA level and <italic>AR</italic> output score (<xref ref-type="bibr" rid="bib8">Cancer Genome Atlas Research Network, 2015</xref>; <xref ref-type="bibr" rid="bib18">Hieronymus et al., 2006</xref>) across the primary prostate tumors from the TCGA dataset, but not <italic>GHRHR</italic> or <italic>KLF8</italic> (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). Consistent with this, increased expression of <italic>GREB1</italic>, but not <italic>GHRHR</italic> or <italic>KLF8</italic>, was observed in TCGA cases with high <italic>AR</italic> scores (top 5%) versus low <italic>AR</italic> scores (bottom 5%) (<xref ref-type="fig" rid="fig2">Figure 2F</xref>, <xref ref-type="supplementary-material" rid="fig2sdata3">Figure 2—source data 3</xref>). To be sure that <italic>GREB1</italic> is relevant in other model systems, we confirmed <italic>GREB1</italic> upregulation in CWR22PC-EP ARsig-hi cells (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>) and reduced <italic>AR</italic> output after <italic>GREB1</italic> knockdown (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). We further validated the knockdown data using CRISPR/Cas9, which also showed inhibition of <italic>AR</italic> output (by flow cytometry) and highly reduced <italic>KLK3</italic> expression in LNCaP ARsig-hi sublines expressing different sgRNAs targeting <italic>GREB1</italic>, without detectable changes in <italic>AR</italic> protein level (<xref ref-type="fig" rid="fig2">Figure 2G,H</xref>).</p></sec><sec id="s2-3"><title>GREB1 amplifies AR transcriptional activity by enhancing AR DNA binding</title><p><italic>GREB1</italic> was first reported as an estrogen-regulated gene in breast cancer (<xref ref-type="bibr" rid="bib28">Rae et al., 2005</xref>) then shown to bind directly to ER, presumably through its LxxLL motif, and function as an ER coactivator by promoting interaction with cofactors (<xref ref-type="bibr" rid="bib23">Mohammed et al., 2013</xref>). To determine if <italic>GREB1</italic> also functions as an <italic>AR</italic> coactivator, we introduced exogenous <italic>GREB1</italic> (HA-GREB1) into ARsig-lo LNCaP and CWR22PC-EP cells and derived stably expressing sublines (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). <italic>GREB1</italic> overexpression enhanced DHT-induced <italic>AR</italic> target gene expression in a dose-dependent manner (<xref ref-type="fig" rid="fig3">Figure 3B,C</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>), indicating that <italic>GREB1</italic> also promotes <italic>AR</italic> activity.</p><fig-group><fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.41913.014</object-id><label>Figure 3.</label><caption><title><italic>GREB1</italic> amplifies <italic>AR</italic> transcriptional activity by enhancing <italic>AR</italic> binding to chromatin.</title><p>(<bold>A</bold>) <italic>GREB1</italic> overexpression in LNCaP ARsig-lo cells with stable integration of a <italic>GREB1</italic> lentiviral vector containing an amino-terminal HA-tag. (<bold>B</bold>) LNCaP ARsig-lo cells with <italic>GREB1</italic> overexpression show higher induction of <italic>AR</italic> target genes in response to DHT treatment. The q-PCR data is presented as mean fold change ±SD relative to the DMSO control. NS = not significant, *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001, unpaired t-test compared to the control cells. (<bold>C</bold>) <italic>GREB1</italic> overexpression in LNCaP ARsig-lo cells increases protein levels of <italic>AR</italic> target genes without affecting <italic>AR</italic> level. (<bold>D</bold>) Co-immunoprecipitation using nuclear extracts shows an interaction between AR and GREB1 (HA) in LNCaP ARsig-lo cells. (<bold>E</bold>) ChIP against the HA-tag shows <italic>GREB1</italic> binding on the <italic>KLK3</italic> and <italic>FKBP5</italic> enhancer regions in LNCaP ARsig-lo cells. *p&lt;0.05, unpaired t-test. (<bold>F–G</bold>) LNCaP ARsig-hi cells have increased <italic>EP300</italic> binding on the <italic>KLK3</italic> and <italic>FKBP5</italic> enhancer regions in a <italic>GREB1</italic> dependent manner. *p&lt;0.05, **p&lt;0.01, unpaired t-test. (<bold>H</bold>) <italic>GREB1</italic> knockdown or CRISPR decreases <italic>AR</italic> binding to <italic>KLK3</italic> enhancer in LNCaP ARsig-hi cells. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, unpaired t-test (shRenilla vs. shGREB1), one-way ANOVA (SgNT vs. SgGREB1). The ChIP q-PCR data (<bold>E–H</bold>) is presented as mean percentage input ±SD. (<bold>I</bold>) Overlap of <italic>AR</italic> ChIP-sequencing peaks shows that <italic>AR</italic> peaks are disrupted by <italic>GREB1</italic> knockdown in LNCaP ARsig-hi cells. (<bold>J</bold>) ChIP-sequencing summary plot shows that <italic>AR</italic> enrichment across the <italic>AR</italic>-binding sites is reduced by <italic>GREB1</italic> knockdown. (<bold>K</bold>) Example of AR genomic peaks at <italic>NKX3-1</italic>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-41913-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.41913.015</object-id><label>Figure 3—figure supplement 1.</label><caption><title><italic>GREB1</italic> amplifies <italic>AR</italic> transcriptional activity in CWR22Pc-EP cells.</title><p>(<bold>A</bold>) <italic>GREB1</italic> overexpression in CWR22Pc-EP ARsig-lo cells with stable integration of <italic>GREB1</italic> lentiviral vector containing HA-tag. *p&lt;0.05, unpaired t-test. (<bold>B</bold>) CWR22Pc-EP ARsig-lo cells with <italic>GREB1</italic> overexpression show higher induction of <italic>AR</italic> target genes in response to DHT treatment. The q-PCR data is presented as mean fold change ±SD relative to the DMSO control. NS = not significant, *p&lt;0.05, unpaired t-test compared to the control cells.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-41913-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.41913.016</object-id><label>Figure 3—figure supplement 2.</label><caption><title><italic>GREB1</italic> enhances <italic>EP300</italic> recruitment to <italic>AR</italic> and <italic>AR</italic> binding to chromatin.</title><p>(<bold>A</bold>) <italic>GREB1</italic> overexpression promotes <italic>EP300</italic> binding to <italic>KLK3</italic> and <italic>FKBP5</italic> enhancer regions in LNCaP ARsig-lo cells. *p&lt;0.05, unpaired t-test. The ChIP q-PCR data is presented as mean percentage input ±SD. (<bold>B</bold>) Knockdown of <italic>EP300</italic> in LNCaP ARsig-lo cells with <italic>GREB1</italic> overexpression suppressed DHT-induced <italic>AR</italic> target gene upregulation. The q-PCR data is presented as mean fold change ±SD relative to the shRenilla (left graph) or DMSO control (right graph). NS = not significant, *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001, one-way ANOVA compared to the shRenilla control. (<bold>C</bold>) <italic>GREB1</italic> overexpression promotes <italic>AR</italic> binding to <italic>KLK3</italic> and <italic>FKBP5</italic> enhancer regions in LNCaP ARsig-lo cells. *p&lt;0.05, unpaired t-test. The ChIP q-PCR data is presented as mean percentage input ±SD. (<bold>D–E</bold>) The location (<bold>D</bold>) and motif (<bold>E</bold>) analysis of the <italic>AR</italic> ChIP-sequencing data shows no difference between peaks affected and not affected by <italic>GREB1</italic> knockdown. (<bold>F–G</bold>) <italic>GREB1</italic> knockdown has no effect on total (<bold>F</bold>) and nuclear (<bold>G</bold>) AR level in both LNCaP ARsig-lo and ARsig-hi cells. TOP2B and tubulin were used as nuclear and cytoplasmic loading controls, respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-41913-fig3-figsupp2-v2.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.41913.017</object-id><label>Figure 3—figure supplement 3.</label><caption><title><italic>GREB1</italic> has a unique function compared to ER or <italic>NCOA1</italic> and <italic>NCOA2</italic>.</title><p>(<bold>A–B</bold>) Knockdown of <italic>GREB1</italic> in MCF7 cells inhibits ER target gene expression (<bold>A</bold>), but has no effect on ER recruitment to binding sites (<bold>B</bold>). (<bold>C–E</bold>) Knockdown of both <italic>NCOA1</italic> and <italic>NCOA2</italic> in LNCaP ARsig-hi cells inhibits AR reporter activity (<bold>C</bold>) and <italic>AR</italic> target gene expression (<bold>D</bold>), but does not affect <italic>AR</italic> binding on <italic>KLK3</italic> and <italic>FKBP5</italic> enhancer regions (<bold>E</bold>). The q-PCR data (<bold>A,D</bold>) is presented as mean fold change ±SD relative to the shRenilla control. The ChIP q-PCR data (<bold>B,E</bold>) is presented as mean percentage input ±SD. NS = not significant, **p&lt;0.01, ****p&lt;0.0001, unpaired t-test (<bold>A,B</bold>), one-way ANOVA (<bold>D,E</bold>) compared to the shRenilla control.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-41913-fig3-figsupp3-v2.tif"/></fig></fig-group><p>In breast cancer, <italic>GREB1</italic> functions as a coactivator through binding to ER and recruitment of the EP300/CBP complex to ER target genes (<xref ref-type="bibr" rid="bib23">Mohammed et al., 2013</xref>). We find that <italic>GREB1</italic> functions similarly in prostate cells, as shown by co-immunoprecipitation documenting AR-GREB1 interaction (<xref ref-type="fig" rid="fig3">Figure 3D</xref>) and ChIP experiments showing recruitment of <italic>GREB1</italic> to <italic>KLK3</italic> and <italic>FKBP5</italic> enhancer regions (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). Furthermore, ARsig-hi cells showed a <italic>GREB1</italic>-dependent increase in <italic>EP300</italic> binding (<xref ref-type="fig" rid="fig3">Figure 3F,G</xref>) and <italic>GREB1</italic> overexpression increased <italic>EP300</italic> recruitment to <italic>AR</italic> target genes in ARsig-lo cells (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A</xref>). Knockdown of <italic>EP300</italic> suppressed the effect of <italic>GREB1</italic> overexpression on DHT-induced <italic>AR</italic> target gene upregulation in ARsig-lo cells (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2B</xref>, refer also to <xref ref-type="fig" rid="fig3">Figure 3B</xref>), suggesting that <italic>EP300</italic> is required for the function of <italic>GREB1</italic> as an <italic>AR</italic> co-factor.</p><p>In addition to this canonical coactivator function of promoting assembly of an active transcription complex, we found that <italic>GREB1</italic> also impacts <italic>AR</italic> DNA binding. For example, knockdown or CRISPR deletion of <italic>GREB1</italic> in ARsig-hi cells significantly reduced binding of <italic>AR</italic> to the <italic>KLK3</italic> enhancer and, conversely, <italic>GREB1</italic> overexpression promoted <italic>AR</italic> recruitment in ARsig-lo cells (<xref ref-type="fig" rid="fig3">Figure 3H</xref>, <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2C</xref>). <italic>AR</italic> ChIP-sequencing revealed that this effect is genome-wide, with a significant reduction in the mean height of <italic>AR</italic> peaks in <italic>GREB1</italic>-depleted cells (<xref ref-type="fig" rid="fig3">Figure 3I–K</xref>). Importantly, the location of <italic>AR</italic> peaks (enhancer, promoter) was identical in intact versus <italic>GREB1</italic> knockdown cells and there were no differences in consensus binding sites (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2D,E</xref>). Therefore, <italic>GREB1</italic> enhances <italic>AR</italic> DNA efficiency but not alter DNA-binding site specificity. As seen previously in our analysis of ARsig-hi cells, total and nuclear <italic>AR</italic> levels were not changed by <italic>GREB1</italic> knockdown or overexpression (<xref ref-type="fig" rid="fig3">Figure 3C</xref>, <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2F,G</xref>).</p><p>Of note, earlier studies of <italic>GREB1</italic> in breast cancer did not report any effect on ER DNA binding (<xref ref-type="bibr" rid="bib23">Mohammed et al., 2013</xref>), which we confirmed by <italic>GREB1</italic> knockdown in MCF7 breast cancer cells (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3A,B</xref>). Thus, <italic>GREB1</italic> functions as a coactivator of both ER and AR but through somewhat different mechanisms. To address the possibility that other hormone receptor coactivators might also function differently in prostate cells, we asked if <italic>NCOA1</italic> and <italic>NCOA2</italic>, previously shown to recruit the EP300/CBP complex to <italic>AR</italic> (<xref ref-type="bibr" rid="bib21">Leo and Chen, 2000</xref>), also influence <italic>AR</italic> DNA binding. To do so, we knocked down both genes in ARsig-hi cells based on prior work showing redundancy between <italic>NCOA1</italic> and <italic>NCOA2</italic> (<xref ref-type="bibr" rid="bib21">Leo and Chen, 2000</xref>; <xref ref-type="bibr" rid="bib38">Wang et al., 2005</xref>). <italic>AR</italic> reporter activity and target gene expression was inhibited in <italic>NCOA1/2</italic>-depleted cells, as expected, but <italic>AR</italic> occupancy of <italic>AR</italic> binding sites was unchanged (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3C–E</xref>). Thus, in addition to a role in EP300/CBP recruitment, <italic>GREB1</italic> has unique effects on <italic>AR</italic> DNA binding that distinguish it from other coactivators.</p></sec><sec id="s2-4"><title>GREB1 is required for enzalutamide resistance of high AR output cells</title><p>Having demonstrated that <italic>GREB1</italic> is overexpressed in ARsig-hi cells and functions as an <italic>AR</italic> coactivator, we asked if <italic>GREB1</italic> is required for maintenance of the ARsig-hi state. First we evaluated the consequences of <italic>GREB1</italic> knockdown on transcription. Consistent with experiments in ARsig-lo cells showing that <italic>GREB1</italic> overexpression enhanced <italic>AR</italic> transcriptional activity (<xref ref-type="fig" rid="fig3">Figure 3B,C</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>), <italic>GREB1</italic> knockdown inhibited baseline and DHT-induced <italic>AR</italic> target gene expression in ARsig-hi cells (<xref ref-type="fig" rid="fig4">Figure 4A–C</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A,B</xref>). RNA-sequencing confirmed enrichment of androgen down-regulated gene sets in <italic>GREB1</italic>-depleted cells (<xref ref-type="fig" rid="fig4">Figure 4D</xref>) as well as downregulation of the 20 <italic>AR</italic> target genes used to calculate the <italic>AR</italic> activity score in TCGA tumors (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>). <italic>GREB1</italic> knockdown cells also showed enrichment of the same prostate basal gene set that was enriched in ARsig-lo cells (<xref ref-type="fig" rid="fig4">Figure 4D</xref>, refer also to <xref ref-type="fig" rid="fig2">Figure 2A</xref>). Additional analysis of RNA-seq data suggests that <italic>GREB1</italic> is a major molecular determinant of the ARsig-hi state: specifically, (i) <italic>GREB1</italic> knockdown impaired the induction of &gt;70% of all DHT-induced genes (<xref ref-type="fig" rid="fig4">Figure 4E</xref>, <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source datas 1</xref> and <xref ref-type="supplementary-material" rid="fig4sdata2">2</xref>) and (ii) the top 100 gene sets enriched in <italic>GREB1</italic>-depleted ARsig-hi cells and ARsig-lo cells show significant overlap (<xref ref-type="fig" rid="fig4">Figure 4F</xref>, <xref ref-type="supplementary-material" rid="fig4sdata3">Figure 4—source data 3</xref>).</p><fig-group><fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.41913.018</object-id><label>Figure 4.</label><caption><title><italic>GREB1</italic> is the major molecular determinant of ARsig-hi cells.</title><p>(<bold>A–B</bold>) Knockdown of <italic>GREB1</italic> inhibited <italic>AR</italic> target gene expression in LNCaP ARsig-hi cells. The q-PCR data (<bold>A</bold>) is presented as mean fold change ±SD relative to the shRenilla control. **p&lt;0.01, ****p&lt;0.0001, unpaired t-test. (<bold>C</bold>) Knockdown of <italic>GREB1</italic> suppressed the enhanced <italic>AR</italic> transcriptional activity in LNCaP ARsig-hi cells. The q-PCR data is presented as mean fold change ±SD relative to the DMSO control. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, unpaired t-test compared to the shRenilla control. (<bold>D</bold>) Gene set enrichment analysis (GSEA) shows that the gene sets up- and down-regulated by androgen are enriched in LNCaP ARsig-hi control and <italic>GREB1</italic> knockdown cells, respectively and genes upregulated in human prostate luminal and basal cells are enriched in ARsig-hi control and <italic>GREB1</italic> depleted cells, respectively. (<bold>E</bold>) Venn diagram showing that 70.5% of DHT-induced genes in control LNCaP ARsig-hi cells were inhibited by <italic>GREB1</italic> knockdown. (<bold>F</bold>) Venn diagram showing that 64% of the top 100 gene sets enriched in LNCaP ARsig-lo overlap with the top 100 gene sets enriched in <italic>GREB1</italic> depleted ARsig-hi cells. (<bold>G</bold>) Knockdown of <italic>GREB1</italic> inhibited development of enzlutamide-resistant LNCaP/AR xenografts derived from ARsig-hi cells. The sorted LNCaP/AR ARsig-hi cells were infected with control or three different shRNAs targeting <italic>GREB1</italic> and injected into physically castrated mice. Mice were treated with enzalutamide immediately after injection. Data is presented as mean ±SEM (N = 10). *p&lt;0.05, **p&lt;0.01, one-way ANOVA compared to the shRenilla control. (<bold>H</bold>) The SU2C cases that have received enzalutamide (Enz) have increased level of <italic>GREB1</italic> (unpaired <italic>t</italic>-test).</p><p><supplementary-material id="fig4sdata1"><object-id pub-id-type="doi">10.7554/eLife.41913.020</object-id><label>Figure 4—source data 1.</label><caption><title>Upregulated genes in ARsig-hi shRenilla DHT vs. veh.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-41913-fig4-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><object-id pub-id-type="doi">10.7554/eLife.41913.021</object-id><label>Figure 4—source data 2.</label><caption><title>Upregulated genes in ARsig-hi shGREB1 DHT vs. veh.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-41913-fig4-data2-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4sdata3"><object-id pub-id-type="doi">10.7554/eLife.41913.022</object-id><label>Figure 4—source data 3.</label><caption><title>GSEA Results (ARsig-hi shRenilla DHT vs. shGREB1 DHT).</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-41913-fig4-data3-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-41913-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.41913.019</object-id><label>Figure 4—figure supplement 1.</label><caption><title>Knockdown of <italic>GREB1</italic> inhibits <italic>AR</italic> signaling.</title><p>(<bold>A–B</bold>) Knockdown of <italic>GREB1</italic> inhibited <italic>AR</italic> target gene expression in CWR22Pc-EP ARsig-hi cells. (<bold>C</bold>) Heatmap generated from the RNA-sequencing data shows that the expression of 20 AR target genes used to calculate the AR score are suppressed by <italic>GREB1</italic> knockdown in LNCaP ARsig-hi cells. (<bold>D–E</bold>) Knockdown of <italic>GREB1</italic> in LNCaP/AR ARsig-hi cells inhibited <italic>AR</italic> reporter activity (<bold>D</bold>) and expression of <italic>AR</italic> target genes (<bold>E</bold>). The q-PCR data (<bold>A,E</bold>) is presented as mean fold change ±SD relative to the shRenilla control. **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001, unpaired t-test (<bold>A</bold>), one-way ANOVA (<bold>E</bold>) compared to the shRenilla control. (<bold>F</bold>) The stromal signature score and tumor purity content show no significant change between pre- vs. post-enzalutamide (Enz) treated SU2C cases. NS = not significant, unpaired t-test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-41913-fig4-figsupp1-v2.tif"/></fig></fig-group><p>Earlier we showed that ARsig-hi cells rapidly acquire resistance to enzalutamide (refer to <xref ref-type="fig" rid="fig1">Figure 1I</xref>). To determine the role of <italic>GREB1</italic> in this drug resistant phenotype, we performed knockdown experiments using the LNCaP/AR xenograft. After confirming that <italic>AR</italic> activity was inhibited in ARsig-hi cells (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D,E</xref>), we injected LNCaP/AR ARsig-hi xenografts with <italic>GREB1</italic> shRNAs into castrated mice treated with enzalutamide and found a significant delay in the development of enzalutamide resistance after 10 weeks (<xref ref-type="fig" rid="fig4">Figure 4G</xref>). Clinical data from CRPC patients also supports for a role of <italic>GREB1</italic> in enzalutamide resistance. Although the samples are not matched pre- and post-treatment, we observed an overall increase in <italic>GREB1</italic> expression in those who progressed on enzalutamide treatment (<xref ref-type="fig" rid="fig4">Figure 4H</xref>). When we analyzed tumor purity content and stromal signature score as described previously (<xref ref-type="bibr" rid="bib9">Carter et al., 2012</xref>; <xref ref-type="bibr" rid="bib32">Shah et al., 2017</xref>; <xref ref-type="bibr" rid="bib42">Yoshihara et al., 2013</xref>), no significant difference was observed between samples collected pre- vs. post-treatment (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1F</xref>).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>There is abundant evidence from tumor sequencing studies that genomic alterations in <italic>AR</italic> (amplification and/or mutation) are present in over 50% of CRPC patients (<xref ref-type="bibr" rid="bib8">Cancer Genome Atlas Research Network, 2015</xref>; <xref ref-type="bibr" rid="bib29">Robinson et al., 2015</xref>) and that <italic>AR</italic> amplification is associated with a less favorable clinical response to abiraterone or enzalutamide treatment (<xref ref-type="bibr" rid="bib2">Annala et al., 2018</xref>). Therefore, high levels of <italic>AR</italic> transcriptional output can promote castration-resistant disease progression. Here we show that prostate cancers can amplify <italic>AR</italic> output through increased expression of the dual AR/ER coactivator <italic>GREB1</italic>, in the absence of genomic <italic>AR</italic> alterations. As with genomic <italic>AR</italic> amplification, increased <italic>AR</italic> output driven by high <italic>GREB1</italic> expression is also associated with enzalutamide resistance.</p><p>In addition to demonstrating the importance of transcriptional heterogeneity in drug resistance, we also show that <italic>GREB1</italic> amplifies <italic>AR</italic> activity by a novel two-part mechanism. Similar to canonical coactivators such as <italic>NCOA1/2</italic>, <italic>GREB1</italic> binds <italic>AR</italic> and promotes the assembly of an active transcription complex by recruitment of histone acetyl transferases such as EP300/CBP (<xref ref-type="bibr" rid="bib20">Lee and Lee Kraus, 2001</xref>). However, <italic>GREB1</italic> has the additional property of improving the efficiency of <italic>AR</italic> binding to DNA, which further enhances <italic>AR</italic> transcriptional output. Although conceptually distinct from canonical coactivators, this dual mechanism of <italic>AR</italic> activation is may not be unique to <italic>GREB1</italic>. For example, <italic>TRIM24</italic> has been shown to function as an oncogenic <italic>AR</italic> cofactor and, similar to <italic>GREB1</italic>, knockdown of <italic>TRIM24</italic> impairs recruitment of <italic>AR</italic> to target genes (<xref ref-type="bibr" rid="bib17">Groner et al., 2016</xref>). Curiously, the effect of <italic>GREB1</italic> on <italic>AR</italic> DNA binding is not seen with ER, suggesting different conformational consequences of <italic>GREB1</italic> binding on AR and ER, respectively, then influence DNA binding.</p><p>One curious observation is the fact that prostate cancers can maintain transcriptional heterogeneity as a stable phenotype, despite the fact that <italic>GREB1</italic> expression drives a feed forward loop which, in principle, should result in an increased fraction of high <italic>AR</italic> output cells over time. One potential explanation for the ability of these populations to maintain stable proportions of high versus low <italic>AR</italic> output cells at steady state is the fact that androgen has growth inhibitory effects at higher concentrations (<xref ref-type="bibr" rid="bib12">Culig et al., 1999</xref>). Because <italic>GREB1</italic> amplifies the magnitude of <italic>AR</italic> output in response to normal (growth stimulatory) androgen concentrations, the biologic consequence of high <italic>GREB1</italic> levels could be the same growth suppression seen with high androgen concentrations. This model predicts that high <italic>AR</italic> output cells would gain a fitness advantage under conditions of androgen deprivation or pharmacologic <italic>AR</italic> inhibition, as demonstrated by the enzalutamide resistance observed in xenograft models.</p><p>Further work is required to understand the clinical implications of our work, particularly whether <italic>GREB1</italic> levels in CRPC patients are predictive of response to next generation <italic>AR</italic> therapy. While we show that <italic>GREB1</italic> levels are elevated in the tumors of CRPC patients who have progressed on enzalutamide, it will be important to address this question prospectively, prior to next generation <italic>AR</italic> therapy. It is also important to note that the positive correlation of <italic>GREB1</italic> levels with high <italic>AR</italic> activity is largely based on the hormone-naïve TCGA cohort. It is also possible that the LNCaP cell line used for functional studies has an <italic>AR</italic> point mutation could potentially influence response to <italic>GREB1</italic> expression, but we obtained similar results in 22PC cells that lack this mutation (<xref ref-type="bibr" rid="bib37">Veldscholte et al., 1992</xref>). In terms of therapeutic implications, <italic>GREB1</italic> knockdown experiments provide genetic evidence that <italic>GREB1</italic> is required for in vivo enzalutamide resistance in xenograft models. Although pharmacologic strategies to inhibit <italic>GREB1</italic> function are not currently available, a small molecule inhibitor that blocks protein-protein interactions between the AR N-terminal domain and CBP/EP300 is currently in clinical development (<xref ref-type="bibr" rid="bib1">Andersen et al., 2010</xref>) (NCT02606123). This work provides precedent that similar strategies to disrupt GREB1/AR interaction may be possible.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th>Reagent type <break/>(species) or <break/>resource</th><th>Designation</th><th>Source or <break/>reference</th><th>Identifiers</th><th>Additional <break/>information</th></tr></thead><tbody><tr><td>Cell line <break/>(<italic>H. sapiens</italic>)</td><td>LNCaP</td><td>ATCC</td><td>CRL-1740, <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_1379">CVCL_1379</ext-link></td><td/></tr><tr><td>Cell line <break/>(<italic>H. sapiens</italic>)</td><td>LNCaP/AR</td><td>PMID: 14702632</td><td/><td/></tr><tr><td>Cell line <break/>(<italic>H. sapiens</italic>)</td><td>CWR22Pc-EP</td><td>PMID: 28059768</td><td/><td/></tr><tr><td>Antibody</td><td valign="bottom">AR</td><td>abcam</td><td valign="bottom">ab108341, <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10865716">AB_10865716</ext-link></td><td>WB (1:1000), <break/>IP (5 ug/IP)</td></tr><tr><td>Antibody</td><td valign="bottom">AR</td><td valign="bottom">Santa Cruz</td><td>sc-816, <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_1563391">AB_1563391</ext-link></td><td>IF (1:500), <break/>ChIP (5 ug/IP)</td></tr><tr><td>Antibody</td><td valign="bottom">AR</td><td valign="bottom">Agilent</td><td>441</td><td>IHC</td></tr><tr><td>Antibody</td><td>KLK3</td><td valign="bottom">Cell Signaling <break/>Technology</td><td valign="bottom">5365</td><td>WB (1:500)</td></tr><tr><td>Antibody</td><td>KLK3</td><td valign="bottom">Biogenex</td><td/><td>IHC</td></tr><tr><td>Antibody</td><td valign="bottom">FKBP5</td><td valign="bottom">Cell Signaling <break/>Technology</td><td>8245, <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10831198">AB_10831198</ext-link></td><td>WB (1:500)</td></tr><tr><td>Antibody</td><td valign="bottom">TRPM8</td><td valign="bottom">Epitomics</td><td valign="bottom">3466–1, <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10715643">AB_10715643</ext-link></td><td>WB (1:1000)</td></tr><tr><td>Antibody</td><td valign="bottom">tubulin</td><td valign="bottom">Santa Cruz</td><td valign="bottom">sc-9104, <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2241191">AB_2241191</ext-link></td><td>WB (1:1000)</td></tr><tr><td>Antibody</td><td valign="bottom">Cyclophilin B</td><td>abcam</td><td valign="bottom">ab178397</td><td>WB (1:100,000)</td></tr><tr><td>Antibody</td><td valign="bottom">BRD4</td><td valign="bottom">Cell Signaling <break/>Technology</td><td valign="bottom">13440, <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2687578">AB_2687578</ext-link></td><td>WB (1:1000)</td></tr><tr><td>Antibody</td><td valign="bottom">TOP2B</td><td>abcam</td><td valign="bottom">ab58442, <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_883147">AB_883147</ext-link></td><td>WB (1:1000)</td></tr><tr><td>Antibody</td><td valign="bottom">HA</td><td valign="bottom">Cell Signaling</td><td valign="bottom">3724, <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_1549585">AB_1549585</ext-link></td><td>WB (1:1000)</td></tr><tr><td>Antibody</td><td valign="bottom">HA</td><td valign="bottom">Abcam</td><td valign="bottom">ab9110, <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_307019">AB_307019</ext-link></td><td>ChIP (5 ug/IP)</td></tr><tr><td>Antibody</td><td valign="bottom">Alexa Fluor 647</td><td>Invitrogen/ <break/>Thermo Fisher</td><td valign="bottom">A-31573, <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2536183">AB_2536183</ext-link></td><td>IF (1:1000)</td></tr><tr><td>Antibody</td><td valign="bottom">p300</td><td valign="bottom">Santa Cruz</td><td valign="bottom">sc-585, <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2231120">AB_2231120</ext-link></td><td>ChIP (5 ug/IP)</td></tr><tr><td>Antibody</td><td valign="bottom">ER</td><td valign="bottom">Santa Cruz</td><td valign="bottom">sc-8002, <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_627558">AB_627558</ext-link></td><td>ChIP (5 ug/IP)</td></tr><tr><td>Antibody</td><td valign="bottom">normal rabbit IgG</td><td>Millipore Sigma</td><td>12–370, <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_145841">AB_145841</ext-link></td><td>ChIP (5 ug/IP)</td></tr><tr><td>Antibody</td><td valign="bottom">Protein A/G <break/>agarose beads</td><td valign="bottom">Santa Cruz</td><td valign="bottom">sc-2003, <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10201400">AB_10201400</ext-link></td><td valign="bottom"/></tr><tr><td>Recombinant <break/>DNA reagent</td><td>ARR3tk-eGFP/ <break/>SV40-mCherry</td><td>This paper</td><td/><td valign="bottom">Addgene plasmid <break/>#24304</td></tr><tr><td>Recombinant <break/>DNA reagent</td><td valign="bottom">SCEP-shRenilla</td><td>This paper, <break/>PMID: 24332856</td><td/><td/></tr><tr><td>Recombinant <break/>DNA reagent</td><td valign="bottom">SCEP-shAR.177</td><td>This paper, <break/>PMID: 24332856</td><td/><td/></tr><tr><td>Recombinant <break/>DNA reagent</td><td valign="bottom">SCEP-shGREB1-1</td><td>This paper, <break/>PMID: 24332856</td><td/><td/></tr><tr><td>Recombinant <break/>DNA reagent</td><td valign="bottom">SCEP-shGREB1-2</td><td>This paper, <break/>PMID: 24332856</td><td/><td/></tr><tr><td>Recombinant <break/>DNA reagent</td><td valign="bottom">SCEP-shGREB1-3</td><td>This paper, <break/>PMID: 24332856</td><td/><td/></tr><tr><td>Recombinant <break/>DNA reagent</td><td valign="bottom">SCEP-shKLF8.3467</td><td>This paper, <break/>PMID: 24332856</td><td/><td/></tr><tr><td>Recombinant <break/>DNA reagent</td><td valign="bottom">SCEP-shKLF8.2180</td><td>This paper, <break/>PMID: 24332856</td><td/><td/></tr><tr><td>Recombinant <break/>DNA reagent</td><td valign="bottom">SCEP-shKLF8.2684</td><td>This paper, <break/>PMID: 24332856</td><td/><td/></tr><tr><td>Recombinant <break/>DNA reagent</td><td valign="bottom">SCEP-shGHRHR.544</td><td>This paper, <break/>PMID: 24332856</td><td/><td/></tr><tr><td>Recombinant <break/>DNA reagent</td><td valign="bottom">SCEP-shGHRHR.1571</td><td>This paper, <break/>PMID: 24332856</td><td/><td/></tr><tr><td>Recombinant <break/>DNA reagent</td><td valign="bottom">SCEP-shGHRHR.1583</td><td>This paper, <break/>PMID: 24332856</td><td/><td/></tr><tr><td>Recombinant <break/>DNA reagent</td><td valign="bottom">SCEP-sh-p300-1</td><td>This paper, <break/>PMID: 24332856</td><td/><td/></tr><tr><td>Recombinant <break/>DNA reagent</td><td valign="bottom">SCEP-sh-p300-2</td><td>This paper, <break/>PMID: 24332856</td><td/><td/></tr><tr><td>Recombinant <break/>DNA reagent</td><td valign="bottom">SCEP-shSRC1-1</td><td>This paper, <break/>PMID: 24332856</td><td/><td/></tr><tr><td>Recombinant <break/>DNA reagent</td><td valign="bottom">SCEP-shSRC2-1</td><td>This paper, <break/>PMID: 24332856</td><td/><td/></tr><tr><td>Recombinant <break/>DNA reagent</td><td valign="bottom">SCEP-shSRC2-2</td><td>This paper, <break/>PMID: 24332856</td><td/><td/></tr><tr><td>Recombinant <break/>DNA reagent</td><td valign="bottom">lentiCRISPRv2-SgNT</td><td>PMID: 24336569</td><td/><td valign="bottom">Addgene <break/>plasmid #52961</td></tr><tr><td>Recombinant <break/>DNA reagent</td><td valign="bottom">lentiCRISPRv2- <break/>SgGREB1-7</td><td>This paper</td><td/><td valign="bottom">Addgene <break/>plasmid #52961</td></tr><tr><td>Recombinant <break/>DNA reagent</td><td valign="bottom">lentiCRISPRv2- <break/>SgGREB1-8</td><td>This paper</td><td/><td valign="bottom">Addgene <break/>plasmid #52961</td></tr><tr><td>Recombinant <break/>DNA reagent</td><td valign="bottom">pCMV6-GREB1</td><td>PMID: 23403292</td><td/><td valign="bottom"/></tr><tr><td>Recombinant <break/>DNA reagent</td><td valign="bottom">pLVX-TRE3G- <break/>HA-GREB1</td><td>This paper</td><td/><td valign="bottom"/></tr><tr><td>Sequence- <break/>based reagent</td><td valign="bottom">q-PCR primers</td><td>This paper</td><td valign="bottom"/><td valign="bottom">See <break/><xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref></td></tr><tr><td>Sequence- <break/>based reagent</td><td valign="bottom">shRNAs</td><td>This paper</td><td valign="bottom"/><td valign="bottom"/></tr><tr><td>Sequence- <break/>based reagent</td><td valign="bottom">gRNAs</td><td>This paper</td><td valign="bottom"/><td valign="bottom"/></tr><tr><td>Commercial <break/>assay or kit</td><td valign="bottom">QIAshredder</td><td valign="bottom">Qiagen</td><td valign="bottom">79656</td><td valign="bottom"/></tr><tr><td>Commercial <break/>assay or kit</td><td valign="bottom">RNeasy Mini Kit</td><td valign="bottom">Qiagen</td><td valign="bottom">74106</td><td valign="bottom"/></tr><tr><td>Commercial <break/>assay or kit</td><td valign="bottom">High Capacity <break/>cDNA Reverse <break/>Transcription Kit</td><td valign="bottom">thermo fisher</td><td valign="bottom">4368814</td><td valign="bottom"/></tr><tr><td>Commercial <break/>assay or kit</td><td valign="bottom">QuantiFast SYBR <break/>Green PCR Kit</td><td valign="bottom">Qiagen</td><td valign="bottom">204057</td><td valign="bottom"/></tr><tr><td>Commercial <break/>assay or kit</td><td valign="bottom">BCA Protein Assay</td><td valign="bottom">ThermoFisher</td><td valign="bottom">23225</td><td valign="bottom"/></tr><tr><td>Commercial <break/>assay or kit</td><td valign="bottom">Subcellular Protein <break/>Fractionation Kit</td><td valign="bottom">ThermoFisher</td><td valign="bottom">78840</td><td valign="bottom"/></tr><tr><td>Commercial <break/>assay or kit</td><td valign="bottom">Peira TM900 system</td><td valign="bottom">Peira bvba</td><td valign="bottom"/><td valign="bottom"/></tr><tr><td>Commercial <break/>assay or kit</td><td valign="bottom">the KAPA Biosystems <break/>Hyper Library <break/>Prep Kit</td><td valign="bottom">Kapa Biosystems</td><td valign="bottom">KK8504</td><td valign="bottom"/></tr><tr><td>Chemical <break/>compound, drug</td><td valign="bottom">FBS</td><td valign="bottom">Omega Scientific</td><td valign="bottom">FB-11</td><td valign="bottom"/></tr><tr><td>Chemical <break/>compound, drug</td><td valign="bottom">Accumax</td><td valign="bottom">Innovative Cell <break/>Technologies</td><td valign="bottom">AM105</td><td valign="bottom"/></tr><tr><td>Chemical <break/>compound, drug</td><td valign="bottom">matrigel</td><td valign="bottom">Corning</td><td valign="bottom">356237</td><td valign="bottom"/></tr><tr><td>Chemical <break/>compound, drug</td><td valign="bottom">Laemmli sample <break/>buffer</td><td valign="bottom">BioRad</td><td valign="bottom">1610747</td><td valign="bottom"/></tr><tr><td>Chemical <break/>compound, drug</td><td valign="bottom">4% formaldehyde</td><td valign="bottom">electron microscopy <break/>sciences</td><td valign="bottom">15714 s</td><td valign="bottom"/></tr><tr><td>Chemical <break/>compound, drug</td><td valign="bottom">normal goat serum</td><td valign="bottom">Vector Lab</td><td valign="bottom">S-1000, <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2336615">AB_2336615</ext-link></td><td valign="bottom"/></tr><tr><td>Chemical <break/>compound, drug</td><td valign="bottom">normal horse serum</td><td valign="bottom">Vector Lab</td><td valign="bottom">S-2000, <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2336617">AB_2336617</ext-link></td><td valign="bottom"/></tr><tr><td>Chemical <break/>compound, drug</td><td valign="bottom">10% Triton X- <break/>100 solution</td><td valign="bottom">Teknova</td><td valign="bottom">T1105</td><td valign="bottom"/></tr><tr><td>Chemical <break/>compound, drug</td><td valign="bottom">DAPI mounting <break/>solution</td><td valign="bottom">Vector Lab</td><td valign="bottom">H-1200, <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2336790">AB_2336790</ext-link></td><td valign="bottom"/></tr><tr><td>Chemical <break/>compound, drug</td><td valign="bottom">charcoal-stripped <break/>dextran-treated fetal <break/>bovine serum</td><td valign="bottom">Omega Scientific</td><td valign="bottom">FB-04</td><td valign="bottom"/></tr><tr><td>Chemical <break/>compound, drug</td><td valign="bottom">Puromycin</td><td valign="bottom">Invivogen</td><td valign="bottom">ant-pr</td><td valign="bottom"/></tr><tr><td>Chemical <break/>compound, drug</td><td valign="bottom">RPMI</td><td valign="bottom">Media Preparation <break/>Core at Sloan <break/>Kettering Institute</td><td valign="bottom"/><td valign="bottom"/></tr><tr><td>Chemical <break/>compound, drug</td><td valign="bottom">DMEM</td><td valign="bottom">Media Preparation <break/>Core at Sloan <break/>Kettering Institute</td><td valign="bottom"/><td valign="bottom"/></tr><tr><td>Software, <break/>algorithm</td><td valign="bottom">Partek Genomics <break/>Suite software</td><td valign="bottom">Partek Inc</td><td valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_011860">SCR_011860</ext-link></td><td valign="bottom"/></tr><tr><td>Software, <break/>algorithm</td><td valign="bottom">FlowJo software</td><td valign="bottom">FlowJo software</td><td valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_008520">SCR_008520</ext-link></td><td valign="bottom">version 9.9.6</td></tr><tr><td>Software, <break/>algorithm</td><td valign="bottom">GSEA</td><td valign="bottom">Broad Institute</td><td valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_003199">SCR_003199</ext-link></td><td valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://www.broadinstitute.org/gsea/index.jsp">http://www.broadinstitute.org/gsea/index.jsp</ext-link></td></tr><tr><td>Software, <break/>algorithm</td><td valign="bottom">GraphPad Prism</td><td valign="bottom">GraphPad Prism</td><td valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002798">SCR_002798</ext-link></td><td valign="bottom">version 7</td></tr><tr><td>Software, <break/>algorithm</td><td valign="bottom">STAR aligner</td><td valign="bottom">PMID: 23104886</td><td valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_015899">SCR_015899</ext-link></td><td valign="bottom"/></tr><tr><td>Software, <break/>algorithm</td><td valign="bottom">Kalisto</td><td valign="bottom">PMID: 27043002</td><td valign="bottom"/><td valign="bottom"/></tr><tr><td>Software, <break/>algorithm</td><td valign="bottom">RSeQC</td><td valign="bottom">PMID: 22743226</td><td valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_005275">SCR_005275</ext-link></td><td valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://broadinstitute.github.io/picard/">http://broadinstitute.github.io/picard/</ext-link></td></tr><tr><td>Software, <break/>algorithm</td><td valign="bottom">DESeq2 package</td><td valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://www-huber.embl.de/users/anders/DESeq">http://www-huber.embl.de/users/anders/DESeq</ext-link></td><td valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_015687">SCR_015687</ext-link></td><td valign="bottom"/></tr><tr><td>Software, <break/>algorithm</td><td valign="bottom">Picard</td><td valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://broadinstitute.github.io/picard/index.html">http://broadinstitute.github.io/pica</ext-link><ext-link ext-link-type="uri" xlink:href="http://broadinstitute.github.io/picard/index.html">rd/index.html</ext-link></td><td valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_006525">SCR_006525</ext-link></td><td valign="bottom"/></tr><tr><td>Software, <break/>algorithm</td><td valign="bottom">MACS2</td><td valign="bottom">PMID: 22936215</td><td valign="bottom"/><td valign="bottom"/></tr><tr><td>Software, <break/> algorithm</td><td valign="bottom">ChAsE</td><td valign="bottom">PMID: 27378294</td><td valign="bottom"/><td valign="bottom"/></tr><tr><td>Software, <break/>algorithm</td><td valign="bottom">MEME-ChIP</td><td valign="bottom">PMID: 21486936</td><td valign="bottom"/><td valign="bottom"/></tr><tr><td>Software, <break/>algorithm</td><td valign="bottom">HOMER</td><td valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://homer.ucsd.edu/homer/">http://homer.ucsd.edu/homer/</ext-link></td><td valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_010881">SCR_010881</ext-link></td><td valign="bottom"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Cell lines</title><p>LNCaP and MCF7 cell lines were obtained from American Type Culture Collection (ATCC, Manassas, VA) and maintained in RPMI (LNCaP) or DMEM (MCF7) +10% FBS (Omega Scientific, Tarzana, CA). LNCaP/AR cell line was generated and maintained as previously described (<xref ref-type="bibr" rid="bib10">Chen et al., 2004</xref>). CWR22Pc was a gift from Marja T. Nevalainen (Thomas Jefferson University, Philadelphia, PA) and CWR22Pc-EP was generated and maintained as previously described (<xref ref-type="bibr" rid="bib24">Mu et al., 2017</xref>). Cell lines were authenticated by exome sequencing methods, and were negative for mycoplasma contamination testing.</p></sec><sec id="s4-2"><title>Flow cytometry analysis and FACS-sorting</title><p>Rapidly cycling eGFP <italic>AR</italic> reporter cells were collected using Accumax dissociation solution (Innovative Cell Technologies, San Diego, CA), and dead cells were counterstained with DAPI (Invitrogen, Grand Island, NY). For FACS-sorting of ARsig-lo and ARsig-hi cells, 5% of the entire population with lowest and highest eGFP expression was sorted out using BD FACSAria cell sorter. The 5% cutoff was used because it generates at least a 100-fold difference in median AR-GFP reporter signal between ARsig-lo and ARsig-hi cells and also allows us to have sufficient numbers of sorted cells to conduct various assays. For flow cytometric analysis of reporter activity, eGFP expression was measured using the BD-LDRII flow cytometer and analysis was done using FlowJo software.</p></sec><sec id="s4-3"><title>Plasmid construction and cell transduction</title><p>The lentiviral eGFP <italic>AR</italic> reporter (ARR<sub>3</sub>tk-eGFP/SV40-mCherry) was generated by switching 7xTcf promoter of 7xTcf-eGFP/SV40-mCherry (Addgene, Cambridge, MA, 24304) with probasin promoter containing 3xARE (ARR<sub>3</sub>tk) (<xref ref-type="bibr" rid="bib34">Snoek et al., 1998</xref>). For shRNA knockdown experiments, SCEP vector was generated by substituting GFP cassette of SGEP (pRRL-GFP-miRE- PGK-PuroR, gift from Johannes Zuber) (<xref ref-type="bibr" rid="bib14">Fellmann et al., 2013</xref>) with mCherry cassette. The following guide sequences were used for knockdown:</p><p>shAR.177: TAGTGCAATCATTTCTGCTGGC</p><p>shGREB1-1: TTGTCAGGAACAGACACTGGTT</p><p>shGREB1-2: TTTCAGATTTATATGATTGGAG</p><p>shGREB1-3: TTGACAAGATACCTAAAGCCGA</p><p>shKLF8.3467: TTGAGTTCTAAAGTTTTCCTGA</p><p>shKLF8.2180: TATTTGTCCAAATTTAACCTAA</p><p>shKLF8.2684: TTATAAAACAATCTGATTGGGC</p><p>shGHRHR.544: TAAAAGTGGTGAACAGCTGGGT</p><p>shGHRHR.1571: TTTATTGGCTCCTCTGAGCCTT</p><p>shGHRHR.1583: TTCATTTACAGGTTTATTGGCT</p><p>shEP300-1: TCCAGAAAGAACTAGAAGAAAA</p><p>shEP300-2: TTAATCTATCTTCAGTAGCTTG</p><p>shNCOA1-1: TTCTTCTTGGAACTTGTCGTTT</p><p>shNCOA2-1: TTGCTGAACTTGCTGTTGCTGA</p><p>shNCOA2-2: TTAACTTTGCTCTTCTCCTTGC</p><p>shRenilla was previously described as Ren.713 targeting Renilla luciferase (<xref ref-type="bibr" rid="bib14">Fellmann et al., 2013</xref>). Pools of 3 shRNAs were used to knockdown <italic>GREB1</italic>, <italic>KLF8</italic> and <italic>GHRHR</italic> in a small-scale shRNA screen, and shGREB1-1 was used for further studies. For CRISPR/Cas9 experiments, lentiCRISPRv2 vector gifted by F. Zhang (Addgene, 52961) was used with the following guide sequences designed using <ext-link ext-link-type="uri" xlink:href="http://crispr.mit.edu/">http://crispr.mit.edu/</ext-link> website:</p><p>SgGREB1-7: AGGCATGTCCTGCGTGCCGC</p><p>SgGREB1-8: TCACGGGCATACGAGCAGTA sgNT was previously described (<xref ref-type="bibr" rid="bib40">Wang et al., 2014</xref>). pCMV6-GREB1 plasmid was a gift from J. Carroll (Cancer Research UK Cambridge Institute, Cambridge, UK). The lentiviral <italic>GREB1</italic> cDNA plasmid was constructed by cloning <italic>GREB1</italic> cDNA from pCMV6-GREB1 into Tet-inducible pLV-based lentiviral expression vector with HA-tag.</p><p>Lentiviral transduction of cells was performed as described previously (<xref ref-type="bibr" rid="bib24">Mu et al., 2017</xref>). To make <italic>AR</italic> reporter cell line, cells were infected with ARR<sub>3</sub>tk-eGFP/SV40-mCherry at low multiplicity of infection (MOI) to enable each cell has one copy of reporter construct, and the transduced cells were sorted by mCherry flow cytometry. To inactivate <italic>GREB1</italic> gene, we single-cell cloned the cells infected with lentiCRISPRv2 vector containing SgGREB1-7 or SgGREB1-8, and isolated a clone that had genomic alteration at target sequence. Three clones were generated by using SgGREB1-7 (SgGREB1-7-2, 7–11 and 7–12) and one clone was generated by using SgGREB1-8 (SgGREB1-8-2).</p></sec><sec id="s4-4"><title>shRNA screen</title><p>FACS-based small-scale shRNA screen with 33 selected genes was performed as follows: FACS-sorted ARsig-hi cells were plated in 12 well plate (1.5 × 10<sup>5</sup> cells per well, Corning, 353043) and each well was infected with pool of 3 SEPC shRNAs against each gene on the following day. Cells with stable integration of hairpins were selected with 2 μg/ml puromycin. 9 days after infection, half of the cells in each well was used to analyze eGFP <italic>AR</italic> reporter activity using flow cytometry, and the other half was subjected to qRT-PCR to determine knockdown level of the gene. We performed the screen in duplicate and each replicate included wells infected with shRenilla or shAR as controls. The median fluorescence intensity (MFI) of eGFP was measured using FlowJo software. The shRNAs decreased eGFP MFI more than 1.5 fold compared to shRenilla (normalized value lower than 0.667) in both duplicate were considered as hits. The list of 33 genes used in the screen and the summary of median eGFP intensity can be found at <xref ref-type="supplementary-material" rid="fig2sdata2">Figure 2—source data 2</xref>.</p></sec><sec id="s4-5"><title>Xenograft assay</title><p>To compare time to acquire enzalutamide resistance in vivo, FACS-sorted bulk, ARsig-lo and ARsig-hi populations derived from LNCaP/AR were cultured for 6 days after sorting to obtain enough number of cells for xenograft assay. 2 × 10<sup>6</sup> cells were injected subcutaneously into the flank of physically castrated CB17 SCID mice in a 50:50 mix of matrigel (BD Biosciences, San Jose, CA) and regular culture medium (five mice, 10 tumors per group), and enzalutamide treatment was initiated on the day of injection. To test the effect of GREB1 knockdown on development of enzalutamide resistance, FACS-sorted ARsig-hi population derived from LNCaP/AR was infected with control or three different shGREB1 constructs 2 days after sorting. Cells with stable integration of hairpin were selected with 2 μg/ml puromycin. 5 days after infection, 2 × 10<sup>6</sup> cells were injected subcutaneously into the flank of castrated CB17 SCID mice (five mice, 10 tumors per group), and enzalutamide treatment was initiated on the day of injection. The same cell populations used for injection were also used to test eGFP <italic>AR</italic> reporter activity using flow cytometry, and qRT-PCR to test knockdown level of <italic>GREB1</italic>. Measurements were obtained weekly using Peira TM900 system (Peira bvba, Belgium). All animal experiments were performed in compliance with the approved institutional animal care and use committee (IACUC) protocols (#06-07-012) of the Research Animal Resource Center of Memorial Sloan Kettering Cancer Center.</p></sec><sec id="s4-6"><title>Immunoblot, immunoprecipitation and immunostaining</title><p>Protein was extracted from cells using Triton lysis buffer and quantified by BCA Protein Assay (ThermoFisher Scientific, Waltham, MA, 23225). Nuclear/cytoplasmic fractionation was achieved with Subcellular Protein Fractionation Kit (ThermoFisher Scientific, 78840). Protein lysates were subjected to SDS-PAGE and immunoblotted with the following antibodies against: AR (Abcam, Cambridge, United Kingdom, ab108341), KLK3 (Cell Signaling Technology, Danvers, MA, 5365), FKBP5 (Cell Signaling, 8245) TRPM8 (Epitomics, Burlingame, CA, 3466–1), tubulin (Santa Cruz Biotechnology, Dallas, TX, sc-9104), Cyclophilin B (Abcam, ab178397), BRD4 (Cell Signaling, 13440), TOP2B (Abcam, ab58442), HA (Cell Signaling, 3724).</p><p>For AR immunoprecipitation, at least 1.5 mg of total protein was incubated with AR antibody (Abcam, ab108341) overnight at 4°C followed by the addition of Protein A/G agarose beads (Santa Cruz, sc-2003) for 2 hr. Immune complexes were extensively washed with Triton buffer and solubilized using Laemmli sample buffer (BioRad, Hercules, CA).</p><p>For immunofluorescence staining, cells were fixed with 4% formaldehyde, permeabilized with 0.2% Triton-X, blocked with 5% normal goat and 5% normal horse serum, stained with anti-AR (Santa Cruz, sc-816) primary and Alexa Fluor 647 (Invitrogen) secondary antibodies, and mounted with DAPI mounting solution (Vector Lab, Burlingame, CA). For Immunohistochemistry, tumor sections were stained with anti-AR (Agilent, Santa Clara, CA, 441) and KLK3 (Biogenex, Fremont, CA) antibodies using Leica Bond RX (Leica Biosystems, Wetzlar, Germany).</p></sec><sec id="s4-7"><title>Transcription analysis</title><p>Total RNA was isolated using the QiaShredder kit (Qiagen, Germantown, MD) for cell lysis and the RNeasy kit (Qiagen) for RNA purification. For quantitative PCR with reverse transcription (RT–qPCR), we used the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Grand Island, NY) to synthesize cDNA according to the manufacturer's protocol. Real-time PCR was performed using gene-specific primers and 2X SYBR green quantfast PCR Mix (Qiagen, 1044154). Data were analyzed by the DDCT method using GAPDH as a control gene and normalized to control samples, which were arbitrarily set to 1. To test DHT-induced <italic>AR</italic> target gene upregulation, cells were hormone-deprived in 10% charcoal-stripped dextran-treated fetal bovine serum (Omega Scientific) media for 2 days and then treated with indicated concentration of DHT for 24 hr. Triplicate measurements were made on at least three biological replicates. The primer sequences used for q-PCR are listed at <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p><p>For RNA-seq, library preparation, sequencing and expression analysis were performed by the New York Genome Center. Libraries were prepared using TruSeq Stranded mRNA Library Preparation Kit in accordance with the manufacturer’s instructions and sequenced on an Illumina HiSeq2500 sequencer (rapid run v2 chemistry) with 50 base pair (bp) reads. Partek Genomics Suite software (Partek Inc, St. Louis, MO) was used to analyze differentially expressed genes between ARsig-lo vs. ARsig-hi (Fold change ≥1.5, p&lt;0.05). To analyze RNA-seq data from ARsig-hi cells with shRenilla vs. shGREB1, reads were aligned to the NCBI GRCh37 human reference using STAR aligner (<xref ref-type="bibr" rid="bib13">Dobin et al., 2013</xref>). Quantification of genes annotated in Gencode vM2 were performed using featureCounts and quantification of transcripts using Kalisto (<xref ref-type="bibr" rid="bib7">Bray et al., 2016</xref>). QC were collected with Picard and RSeQC (<xref ref-type="bibr" rid="bib39">Wang et al., 2012</xref>) (<ext-link ext-link-type="uri" xlink:href="http://broadinstitute.github.io/picard/">http://broadinstitute.github.io/picard/</ext-link>). Normalization of feature counts was done using the DESeq2 package (<ext-link ext-link-type="uri" xlink:href="http://www-huber.embl.de/users/anders/DESeq/">http://www-huber.embl.de/users/anders/DESeq/</ext-link>). Differentially expressed genes were defined as a 1.5 fold difference, p&lt;0.05 of DESeq-normalized expression. For GSEA, statistical analysis was performed with publicly available software from the Broad Institute (<ext-link ext-link-type="uri" xlink:href="http://www.broadinstitute.org/gsea/index.jsp">http://www.broadinstitute.org/gsea/index.jsp</ext-link>). The basal and luminal gene signatures used for GSEA (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>) were generated by conducting RNA-sequencing with normal human basal vs. luminal prostate cells isolated as previously described (<xref ref-type="bibr" rid="bib19">Karthaus et al., 2014</xref>). Full description of this study will be reported separately.</p></sec><sec id="s4-8"><title>ChIP</title><p>ChIP experiments were performed as previously described (<xref ref-type="bibr" rid="bib3">Arora et al., 2013</xref>), using SDS-based buffers. Antibodies were used at a concentration of 5 ug per 1 mL of IP buffer, which encompassed approximately 8 million cells per IP. Antibodies used were: AR (Santa Cruz, sc-816), EP300 (Santa Cruz, sc-585), HA (Abcam, ab9110), ER (Santa Cruz, sc-8002). The primer sequences used for ChIP-qPCR are listed at <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p><p>For ChIP–seq, library preparation and RNA-seq were performed by the NYU Genome Technology Center. Libraries were made using the KAPA Biosystems Hyper Library Prep Kit (Kapa Biosystems, Woburn, MA, KK8504), using 10 ng of DNA as input and 10 PCR cycles for library amplification. The libraries were sequenced on a HiSeq 2500, as rapid run v2 chemistry, paired-end mode of 51 bp read length.</p><p>The ChIP-seq reads were aligned to the human genome (hg19, build 37) using the program BWA (VN: 0.7.12; default parameters) within the PEMapper. Duplicated reads were marked by the software Picard (VN: 1.124; <ext-link ext-link-type="uri" xlink:href="http://broadinstitute.github.io/picard/index.html">http://broadinstitute.github.io/picard/index.html</ext-link>) and removed. The software MACS2 (<xref ref-type="bibr" rid="bib15">Feng et al., 2012</xref>) (-q 0.1) was used for peak identification with data from ChIP input DNAs as controls. Peaks of sizes &gt; 100 bp and with at least one base pair covered by &gt;18 reads were selected as the final high confident peaks. Peaks from shGREB1/control conditions were all merged to obtain non-overlapping genomic regions, which were then used to determine conditional specific <italic>AR</italic> binding. Overlapped peaks were defined as those sharing at least one base pair. To generate graphs depicting <italic>AR</italic> ChIP–seq read density in ±2 kilobase regions of the <italic>AR</italic> peak summits, the same number of ChIP–seq reads from different conditions were loaded into the software ChAsE (<xref ref-type="bibr" rid="bib43">Younesy et al., 2016</xref>), and the resulting read density matrices were sorted by the read densities in the shRenilla control, before coloring. The read density was also used to select peaks with significant signal difference between shGREB1 and controls. The criteria for assigning peaks to genes have been described previously (<xref ref-type="bibr" rid="bib30">Rockowitz and Zheng, 2015</xref>). The MEME-ChIP software (<xref ref-type="bibr" rid="bib22">Machanick and Bailey, 2011</xref>) was applied to 300 bp sequences around the peak summits for motif discovery, and the comparison of sequence motifs was also analyzed with HOMER (<ext-link ext-link-type="uri" xlink:href="http://homer.ucsd.edu/homer/">http://homer.ucsd.edu/homer/</ext-link>).</p></sec><sec id="s4-9"><title>Analysis of human prostate cancer datasets</title><p>All analysis of human prostate cancer data was conducted using previously published datasets of The Cancer Genome Atlas (TCGA) (<xref ref-type="bibr" rid="bib8">Cancer Genome Atlas Research Network, 2015</xref>) and PCF/SU2C (<xref ref-type="bibr" rid="bib29">Robinson et al., 2015</xref>), which can be explored in the cBioPortal for Cancer Genomics (<ext-link ext-link-type="uri" xlink:href="http://www.cbioportal.org">http://www.cbioportal.org</ext-link>). Tumor purity content was estimated computationally using the ABSOLUTE method (<xref ref-type="bibr" rid="bib9">Carter et al., 2012</xref>), based on mutant allele variant fractions and zygosity shifts. Stromal signature score was applied to the normalized RNA-seq expression dataset (<xref ref-type="bibr" rid="bib42">Yoshihara et al., 2013</xref>).</p></sec><sec id="s4-10"><title>Statistics</title><p>For comparison of pooled data between two different groups, unpaired t tests were used to determine significance. For comparison of data among three groups, one-way ANOVA was used to determine significance. In vitro assays represent three independent experiments from biological replicates, unless otherwise indicated. In all figures, *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001 and ****p&lt;0.0001. For GSEA, statistical analysis was performed with publicly available software from the Broad Institute (<ext-link ext-link-type="uri" xlink:href="http://www.broadinstitute.org/gsea/index.jsp">http://www.broadinstitute.org/gsea/index.jsp</ext-link>). The sample size estimate was based on our experience with previous experiments (<xref ref-type="bibr" rid="bib4">Balbas et al., 2013</xref>; <xref ref-type="bibr" rid="bib6">Bose et al., 2017</xref>; <xref ref-type="bibr" rid="bib11">Chen et al., 2013</xref>). No formal randomization process was used to assign mice to a given xenograft assay, and experimenters were not blinded.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank the flow cytometry core facility at MSKCC for technical support, NYU Genome Technology Center for conducting ChIP-sequencing, New York Genome Center for conducting the RNA-sequencing, MSKCC Pathology Core for assistance with IHC staining of patient samples, Wouter Karthaus for help with cloning and providing the basal and luminal gene signature, Wassim Abida for help with analyzing patient data, Kayla Lawrence and Tejasveeta Nadkarni for help with cloning and Jason Carroll (Cancer Research UK Cambridge Institute) for generously providing pCMV6-GREB1 plasmid, and the members of the Sawyers laboratory for helpful discussions.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf3"><p>Senior Editor eLife; Board of Directors of Novartis; co-founder of ORIC Pharm; co-inventor of enzalutamide and apalutamide; Science advisor to Agios, Beigene, Blueprint, Column Group, Foghorn, Housey Pharma, Nextech, KSQ, Petra and PMV; co-founder of Seragon, purchased by Genentech/Roche in 2014.</p></fn><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>co-inventor of enzalutamide</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing—original draft, Project administration, Writing—review and editing</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Visualization</p></fn><fn fn-type="con" id="con5"><p>Investigation</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Visualization, Writing—review and editing</p></fn><fn fn-type="con" id="con7"><p>Resources, Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con8"><p>Resources</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Supervision, Funding acquisition, Writing—original draft, Project administration, Writing—review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All animal experiments were performed in compliance with the approved institutional animal care and use committee (IACUC) protocols (#06-07-012) of the Research Animal Resource Center of Memorial Sloan Kettering Cancer Center.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><object-id pub-id-type="doi">10.7554/eLife.41913.023</object-id><label>Supplementary file 1.</label><caption><title>Primer list.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-41913-supp1-v2.xlsx"/></supplementary-material><supplementary-material id="supp2"><object-id pub-id-type="doi">10.7554/eLife.41913.024</object-id><label>Supplementary file 2.</label><caption><title>The basal and luminal gene signatures used for GSEA.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-41913-supp2-v2.xlsx"/></supplementary-material><supplementary-material id="transrepform"><object-id pub-id-type="doi">10.7554/eLife.41913.025</object-id><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-41913-transrepform-v2.pdf"/></supplementary-material><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>RNA-seq data has been deposited in GEO under accession code GSE120720. ChIP-seq data has been deposited in GEO under accession code GSE120680</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>E</given-names></name><name><surname>Wongvipat</surname><given-names>J</given-names></name><name><surname>Choi</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Lee</surname><given-names>YS</given-names></name><name><surname>Zheng</surname><given-names>D</given-names></name><name><surname>Watson</surname><given-names>PA</given-names></name><name><surname>Gopalan</surname><given-names>A</given-names></name><name><surname>Sawyers</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>GREB1 amplifies androgen receptor output in prostate cancer and contributes to antiandrogen resistance</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE120720">GSE120720</pub-id></element-citation></p><p><element-citation id="dataset2" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>E</given-names></name><name><surname>Wongvipat</surname><given-names>J</given-names></name><name><surname>Choi</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Lee</surname><given-names>YS</given-names></name><name><surname>Zheng</surname><given-names>D</given-names></name><name><surname>Watson</surname><given-names>PA</given-names></name><name><surname>Gopalan</surname><given-names>A</given-names></name><name><surname>Sawyers</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>GREB1 amplifies androgen receptor output in prostate cancer and contributes to antiandrogen resistance</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE120680">GSE120680</pub-id></element-citation></p><p>The following previously published datasets were used:</p><p><element-citation id="dataset3" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>D</given-names></name><name><surname>Van</surname><given-names>Allen EM</given-names></name><name><surname>Wu</surname><given-names>YM</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name><name><surname>Lonigro</surname><given-names>RJ</given-names></name><name><surname>Mosquera</surname><given-names>JM</given-names></name><name><surname>Montgomery</surname><given-names>B</given-names></name><name><surname>Taplin</surname><given-names>ME</given-names></name><name><surname>Pritchard</surname><given-names>CC</given-names></name><name><surname>Attard</surname><given-names>G</given-names></name><name><surname>Beltran</surname><given-names>H</given-names></name><name><surname>Abida</surname><given-names>W</given-names></name><name><surname>Bradley</surname><given-names>RK</given-names></name><name><surname>Vinson</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Vats</surname><given-names>P</given-names></name><name><surname>Kunju</surname><given-names>LP</given-names></name><name><surname>Hussain</surname><given-names>M</given-names></name><name><surname>Feng</surname><given-names>FY</given-names></name><name><surname>Tomlins</surname><given-names>SA</given-names></name><name><surname>Cooney</surname><given-names>KA</given-names></name><name><surname>Smith</surname><given-names>DC</given-names></name><name><surname>Brennan</surname><given-names>C</given-names></name><name><surname>Siddiqui</surname><given-names>J</given-names></name><name><surname>Mehra</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Rathkopf</surname><given-names>DE</given-names></name><name><surname>Morris</surname><given-names>MJ</given-names></name><name><surname>Solomon</surname><given-names>SB</given-names></name></person-group><year iso-8601-date="2015">2015</year><data-title>Integrative clinical genomics of advanced prostate cancer</data-title><source>NCBI dbGap</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/gap/?term=phs000915.v1.p1">phs000915.v1.p1</pub-id></element-citation></p><p><element-citation id="dataset4" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Cancer</surname><given-names>Genome Atlas Research Network</given-names></name></person-group><year iso-8601-date="2015">2015</year><data-title>The Molecular Taxonomy of Primary Prostate Cancer</data-title><source>cBioPortal for Cancer Genomics</source><pub-id assigning-authority="NCBI" pub-id-type="archive" xlink:href="http://www.cbioportal.org/study.do?cancer_study_id=prad_tcga_pub">prad_tcga_pub</pub-id></element-citation></p></sec></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname> <given-names>RJ</given-names></name><name><surname>Mawji</surname> <given-names>NR</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>G</given-names></name><name><surname>Haile</surname> <given-names>S</given-names></name><name><surname>Myung</surname> <given-names>JK</given-names></name><name><surname>Watt</surname> <given-names>K</given-names></name><name><surname>Tam</surname> <given-names>T</given-names></name><name><surname>Yang</surname> <given-names>YC</given-names></name><name><surname>Bañuelos</surname> <given-names>CA</given-names></name><name><surname>Williams</surname> <given-names>DE</given-names></name><name><surname>McEwan</surname> <given-names>IJ</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Sadar</surname> <given-names>MD</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor</article-title><source>Cancer Cell</source><volume>17</volume><fpage>535</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2010.04.027</pub-id><pub-id pub-id-type="pmid">20541699</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Annala</surname> <given-names>M</given-names></name><name><surname>Vandekerkhove</surname> <given-names>G</given-names></name><name><surname>Khalaf</surname> <given-names>D</given-names></name><name><surname>Taavitsainen</surname> <given-names>S</given-names></name><name><surname>Beja</surname> <given-names>K</given-names></name><name><surname>Warner</surname> <given-names>EW</given-names></name><name><surname>Sunderland</surname> <given-names>K</given-names></name><name><surname>Kollmannsberger</surname> <given-names>C</given-names></name><name><surname>Eigl</surname> <given-names>BJ</given-names></name><name><surname>Finch</surname> <given-names>D</given-names></name><name><surname>Oja</surname> <given-names>CD</given-names></name><name><surname>Vergidis</surname> <given-names>J</given-names></name><name><surname>Zulfiqar</surname> <given-names>M</given-names></name><name><surname>Azad</surname> <given-names>AA</given-names></name><name><surname>Nykter</surname> <given-names>M</given-names></name><name><surname>Gleave</surname> <given-names>ME</given-names></name><name><surname>Wyatt</surname> <given-names>AW</given-names></name><name><surname>Chi</surname> <given-names>KN</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Circulating tumor dna genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer</article-title><source>Cancer Discovery</source><volume>8</volume><fpage>444</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-17-0937</pub-id><pub-id pub-id-type="pmid">29367197</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arora</surname> <given-names>VK</given-names></name><name><surname>Schenkein</surname> <given-names>E</given-names></name><name><surname>Murali</surname> <given-names>R</given-names></name><name><surname>Subudhi</surname> <given-names>SK</given-names></name><name><surname>Wongvipat</surname> <given-names>J</given-names></name><name><surname>Balbas</surname> <given-names>MD</given-names></name><name><surname>Shah</surname> <given-names>N</given-names></name><name><surname>Cai</surname> <given-names>L</given-names></name><name><surname>Efstathiou</surname> <given-names>E</given-names></name><name><surname>Logothetis</surname> <given-names>C</given-names></name><name><surname>Zheng</surname> <given-names>D</given-names></name><name><surname>Sawyers</surname> <given-names>CL</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade</article-title><source>Cell</source><volume>155</volume><fpage>1309</fpage><lpage>1322</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.11.012</pub-id><pub-id pub-id-type="pmid">24315100</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balbas</surname> <given-names>MD</given-names></name><name><surname>Evans</surname> <given-names>MJ</given-names></name><name><surname>Hosfield</surname> <given-names>DJ</given-names></name><name><surname>Wongvipat</surname> <given-names>J</given-names></name><name><surname>Arora</surname> <given-names>VK</given-names></name><name><surname>Watson</surname> <given-names>PA</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Greene</surname> <given-names>GL</given-names></name><name><surname>Shen</surname> <given-names>Y</given-names></name><name><surname>Sawyers</surname> <given-names>CL</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Overcoming mutation-based resistance to antiandrogens with rational drug design</article-title><source>eLife</source><volume>2</volume><elocation-id>e00499</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.00499</pub-id><pub-id pub-id-type="pmid">23580326</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname> <given-names>MF</given-names></name><name><surname>Lawrence</surname> <given-names>MS</given-names></name><name><surname>Demichelis</surname> <given-names>F</given-names></name><name><surname>Drier</surname> <given-names>Y</given-names></name><name><surname>Cibulskis</surname> <given-names>K</given-names></name><name><surname>Sivachenko</surname> <given-names>AY</given-names></name><name><surname>Sboner</surname> <given-names>A</given-names></name><name><surname>Esgueva</surname> <given-names>R</given-names></name><name><surname>Pflueger</surname> <given-names>D</given-names></name><name><surname>Sougnez</surname> <given-names>C</given-names></name><name><surname>Onofrio</surname> <given-names>R</given-names></name><name><surname>Carter</surname> <given-names>SL</given-names></name><name><surname>Park</surname> <given-names>K</given-names></name><name><surname>Habegger</surname> <given-names>L</given-names></name><name><surname>Ambrogio</surname> <given-names>L</given-names></name><name><surname>Fennell</surname> <given-names>T</given-names></name><name><surname>Parkin</surname> <given-names>M</given-names></name><name><surname>Saksena</surname> <given-names>G</given-names></name><name><surname>Voet</surname> <given-names>D</given-names></name><name><surname>Ramos</surname> <given-names>AH</given-names></name><name><surname>Pugh</surname> <given-names>TJ</given-names></name><name><surname>Wilkinson</surname> <given-names>J</given-names></name><name><surname>Fisher</surname> <given-names>S</given-names></name><name><surname>Winckler</surname> <given-names>W</given-names></name><name><surname>Mahan</surname> <given-names>S</given-names></name><name><surname>Ardlie</surname> <given-names>K</given-names></name><name><surname>Baldwin</surname> <given-names>J</given-names></name><name><surname>Simons</surname> <given-names>JW</given-names></name><name><surname>Kitabayashi</surname> <given-names>N</given-names></name><name><surname>MacDonald</surname> <given-names>TY</given-names></name><name><surname>Kantoff</surname> <given-names>PW</given-names></name><name><surname>Chin</surname> <given-names>L</given-names></name><name><surname>Gabriel</surname> <given-names>SB</given-names></name><name><surname>Gerstein</surname> <given-names>MB</given-names></name><name><surname>Golub</surname> <given-names>TR</given-names></name><name><surname>Meyerson</surname> <given-names>M</given-names></name><name><surname>Tewari</surname> <given-names>A</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Getz</surname> <given-names>G</given-names></name><name><surname>Rubin</surname> <given-names>MA</given-names></name><name><surname>Garraway</surname> <given-names>LA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The genomic complexity of primary human prostate cancer</article-title><source>Nature</source><volume>470</volume><fpage>214</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1038/nature09744</pub-id><pub-id pub-id-type="pmid">21307934</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bose</surname> <given-names>R</given-names></name><name><surname>Karthaus</surname> <given-names>WR</given-names></name><name><surname>Armenia</surname> <given-names>J</given-names></name><name><surname>Abida</surname> <given-names>W</given-names></name><name><surname>Iaquinta</surname> <given-names>PJ</given-names></name><name><surname>Zhang</surname> <given-names>Z</given-names></name><name><surname>Wongvipat</surname> <given-names>J</given-names></name><name><surname>Wasmuth</surname> <given-names>EV</given-names></name><name><surname>Shah</surname> <given-names>N</given-names></name><name><surname>Sullivan</surname> <given-names>PS</given-names></name><name><surname>Doran</surname> <given-names>MG</given-names></name><name><surname>Wang</surname> <given-names>P</given-names></name><name><surname>Patruno</surname> <given-names>A</given-names></name><name><surname>Zhao</surname> <given-names>Y</given-names></name><name><surname>Zheng</surname> <given-names>D</given-names></name><name><surname>Schultz</surname> <given-names>N</given-names></name><name><surname>Sawyers</surname> <given-names>CL</given-names></name><collab>International SU2C/PCF Prostate Cancer Dream Team</collab></person-group><year iso-8601-date="2017">2017</year><article-title>ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis</article-title><source>Nature</source><volume>546</volume><fpage>671</fpage><lpage>675</lpage><pub-id pub-id-type="doi">10.1038/nature22820</pub-id><pub-id pub-id-type="pmid">28614298</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname> <given-names>NL</given-names></name><name><surname>Pimentel</surname> <given-names>H</given-names></name><name><surname>Melsted</surname> <given-names>P</given-names></name><name><surname>Pachter</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Near-optimal probabilistic RNA-seq quantification</article-title><source>Nature Biotechnology</source><volume>34</volume><fpage>525</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1038/nbt.3519</pub-id><pub-id pub-id-type="pmid">27043002</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Cancer Genome Atlas Research Network</collab></person-group><year iso-8601-date="2015">2015</year><article-title>The molecular taxonomy of primary prostate cancer</article-title><source>Cell</source><volume>163</volume><fpage>1011</fpage><lpage>1025</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.10.025</pub-id><pub-id pub-id-type="pmid">26544944</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname> <given-names>SL</given-names></name><name><surname>Cibulskis</surname> <given-names>K</given-names></name><name><surname>Helman</surname> <given-names>E</given-names></name><name><surname>McKenna</surname> <given-names>A</given-names></name><name><surname>Shen</surname> <given-names>H</given-names></name><name><surname>Zack</surname> <given-names>T</given-names></name><name><surname>Laird</surname> <given-names>PW</given-names></name><name><surname>Onofrio</surname> <given-names>RC</given-names></name><name><surname>Winckler</surname> <given-names>W</given-names></name><name><surname>Weir</surname> <given-names>BA</given-names></name><name><surname>Beroukhim</surname> <given-names>R</given-names></name><name><surname>Pellman</surname> <given-names>D</given-names></name><name><surname>Levine</surname> <given-names>DA</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Meyerson</surname> <given-names>M</given-names></name><name><surname>Getz</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Absolute quantification of somatic DNA alterations in human cancer</article-title><source>Nature Biotechnology</source><volume>30</volume><fpage>413</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1038/nbt.2203</pub-id><pub-id pub-id-type="pmid">22544022</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>CD</given-names></name><name><surname>Welsbie</surname> <given-names>DS</given-names></name><name><surname>Tran</surname> <given-names>C</given-names></name><name><surname>Baek</surname> <given-names>SH</given-names></name><name><surname>Chen</surname> <given-names>R</given-names></name><name><surname>Vessella</surname> <given-names>R</given-names></name><name><surname>Rosenfeld</surname> <given-names>MG</given-names></name><name><surname>Sawyers</surname> <given-names>CL</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Molecular determinants of resistance to antiandrogen therapy</article-title><source>Nature Medicine</source><volume>10</volume><fpage>33</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1038/nm972</pub-id><pub-id pub-id-type="pmid">14702632</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Chi</surname> <given-names>P</given-names></name><name><surname>Rockowitz</surname> <given-names>S</given-names></name><name><surname>Iaquinta</surname> <given-names>PJ</given-names></name><name><surname>Shamu</surname> <given-names>T</given-names></name><name><surname>Shukla</surname> <given-names>S</given-names></name><name><surname>Gao</surname> <given-names>D</given-names></name><name><surname>Sirota</surname> <given-names>I</given-names></name><name><surname>Carver</surname> <given-names>BS</given-names></name><name><surname>Wongvipat</surname> <given-names>J</given-names></name><name><surname>Scher</surname> <given-names>HI</given-names></name><name><surname>Zheng</surname> <given-names>D</given-names></name><name><surname>Sawyers</surname> <given-names>CL</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss</article-title><source>Nature Medicine</source><volume>19</volume><fpage>1023</fpage><lpage>1029</lpage><pub-id pub-id-type="doi">10.1038/nm.3216</pub-id><pub-id pub-id-type="pmid">23817021</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Culig</surname> <given-names>Z</given-names></name><name><surname>Hoffmann</surname> <given-names>J</given-names></name><name><surname>Erdel</surname> <given-names>M</given-names></name><name><surname>Eder</surname> <given-names>IE</given-names></name><name><surname>Hobisch</surname> <given-names>A</given-names></name><name><surname>Hittmair</surname> <given-names>A</given-names></name><name><surname>Bartsch</surname> <given-names>G</given-names></name><name><surname>Utermann</surname> <given-names>G</given-names></name><name><surname>Schneider</surname> <given-names>MR</given-names></name><name><surname>Parczyk</surname> <given-names>K</given-names></name><name><surname>Klocker</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system</article-title><source>British Journal of Cancer</source><volume>81</volume><fpage>242</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6690684</pub-id><pub-id pub-id-type="pmid">10496349</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname> <given-names>A</given-names></name><name><surname>Davis</surname> <given-names>CA</given-names></name><name><surname>Schlesinger</surname> <given-names>F</given-names></name><name><surname>Drenkow</surname> <given-names>J</given-names></name><name><surname>Zaleski</surname> <given-names>C</given-names></name><name><surname>Jha</surname> <given-names>S</given-names></name><name><surname>Batut</surname> <given-names>P</given-names></name><name><surname>Chaisson</surname> <given-names>M</given-names></name><name><surname>Gingeras</surname> <given-names>TR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>STAR: ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics</source><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id><pub-id pub-id-type="pmid">23104886</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fellmann</surname> <given-names>C</given-names></name><name><surname>Hoffmann</surname> <given-names>T</given-names></name><name><surname>Sridhar</surname> <given-names>V</given-names></name><name><surname>Hopfgartner</surname> <given-names>B</given-names></name><name><surname>Muhar</surname> <given-names>M</given-names></name><name><surname>Roth</surname> <given-names>M</given-names></name><name><surname>Lai</surname> <given-names>DY</given-names></name><name><surname>Barbosa</surname> <given-names>IA</given-names></name><name><surname>Kwon</surname> <given-names>JS</given-names></name><name><surname>Guan</surname> <given-names>Y</given-names></name><name><surname>Sinha</surname> <given-names>N</given-names></name><name><surname>Zuber</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>An optimized microRNA backbone for effective single-copy RNAi</article-title><source>Cell Reports</source><volume>5</volume><fpage>1704</fpage><lpage>1713</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2013.11.020</pub-id><pub-id pub-id-type="pmid">24332856</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname> <given-names>J</given-names></name><name><surname>Liu</surname> <given-names>T</given-names></name><name><surname>Qin</surname> <given-names>B</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Liu</surname> <given-names>XS</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Identifying ChIP-seq enrichment using MACS</article-title><source>Nature Protocols</source><volume>7</volume><fpage>1728</fpage><lpage>1740</lpage><pub-id pub-id-type="doi">10.1038/nprot.2012.101</pub-id><pub-id pub-id-type="pmid">22936215</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geng</surname> <given-names>C</given-names></name><name><surname>He</surname> <given-names>B</given-names></name><name><surname>Xu</surname> <given-names>L</given-names></name><name><surname>Barbieri</surname> <given-names>CE</given-names></name><name><surname>Eedunuri</surname> <given-names>VK</given-names></name><name><surname>Chew</surname> <given-names>SA</given-names></name><name><surname>Zimmermann</surname> <given-names>M</given-names></name><name><surname>Bond</surname> <given-names>R</given-names></name><name><surname>Shou</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>C</given-names></name><name><surname>Blattner</surname> <given-names>M</given-names></name><name><surname>Lonard</surname> <given-names>DM</given-names></name><name><surname>Demichelis</surname> <given-names>F</given-names></name><name><surname>Coarfa</surname> <given-names>C</given-names></name><name><surname>Rubin</surname> <given-names>MA</given-names></name><name><surname>Zhou</surname> <given-names>P</given-names></name><name><surname>O'Malley</surname> <given-names>BW</given-names></name><name><surname>Mitsiades</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover</article-title><source>PNAS</source><volume>110</volume><fpage>6997</fpage><lpage>7002</lpage><pub-id pub-id-type="doi">10.1073/pnas.1304502110</pub-id><pub-id pub-id-type="pmid">23559371</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Groner</surname> <given-names>AC</given-names></name><name><surname>Cato</surname> <given-names>L</given-names></name><name><surname>de Tribolet-Hardy</surname> <given-names>J</given-names></name><name><surname>Bernasocchi</surname> <given-names>T</given-names></name><name><surname>Janouskova</surname> <given-names>H</given-names></name><name><surname>Melchers</surname> <given-names>D</given-names></name><name><surname>Houtman</surname> <given-names>R</given-names></name><name><surname>Cato</surname> <given-names>ACB</given-names></name><name><surname>Tschopp</surname> <given-names>P</given-names></name><name><surname>Gu</surname> <given-names>L</given-names></name><name><surname>Corsinotti</surname> <given-names>A</given-names></name><name><surname>Zhong</surname> <given-names>Q</given-names></name><name><surname>Fankhauser</surname> <given-names>C</given-names></name><name><surname>Fritz</surname> <given-names>C</given-names></name><name><surname>Poyet</surname> <given-names>C</given-names></name><name><surname>Wagner</surname> <given-names>U</given-names></name><name><surname>Guo</surname> <given-names>T</given-names></name><name><surname>Aebersold</surname> <given-names>R</given-names></name><name><surname>Garraway</surname> <given-names>LA</given-names></name><name><surname>Wild</surname> <given-names>PJ</given-names></name><name><surname>Theurillat</surname> <given-names>JP</given-names></name><name><surname>Brown</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>TRIM24 Is an oncogenic transcriptional activator in prostate cancer</article-title><source>Cancer Cell</source><volume>29</volume><fpage>846</fpage><lpage>858</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2016.04.012</pub-id><pub-id pub-id-type="pmid">27238081</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hieronymus</surname> <given-names>H</given-names></name><name><surname>Lamb</surname> <given-names>J</given-names></name><name><surname>Ross</surname> <given-names>KN</given-names></name><name><surname>Peng</surname> <given-names>XP</given-names></name><name><surname>Clement</surname> <given-names>C</given-names></name><name><surname>Rodina</surname> <given-names>A</given-names></name><name><surname>Nieto</surname> <given-names>M</given-names></name><name><surname>Du</surname> <given-names>J</given-names></name><name><surname>Stegmaier</surname> <given-names>K</given-names></name><name><surname>Raj</surname> <given-names>SM</given-names></name><name><surname>Maloney</surname> <given-names>KN</given-names></name><name><surname>Clardy</surname> <given-names>J</given-names></name><name><surname>Hahn</surname> <given-names>WC</given-names></name><name><surname>Chiosis</surname> <given-names>G</given-names></name><name><surname>Golub</surname> <given-names>TR</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators</article-title><source>Cancer Cell</source><volume>10</volume><fpage>321</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2006.09.005</pub-id><pub-id pub-id-type="pmid">17010675</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karthaus</surname> <given-names>WR</given-names></name><name><surname>Iaquinta</surname> <given-names>PJ</given-names></name><name><surname>Drost</surname> <given-names>J</given-names></name><name><surname>Gracanin</surname> <given-names>A</given-names></name><name><surname>van Boxtel</surname> <given-names>R</given-names></name><name><surname>Wongvipat</surname> <given-names>J</given-names></name><name><surname>Dowling</surname> <given-names>CM</given-names></name><name><surname>Gao</surname> <given-names>D</given-names></name><name><surname>Begthel</surname> <given-names>H</given-names></name><name><surname>Sachs</surname> <given-names>N</given-names></name><name><surname>Vries</surname> <given-names>RGJ</given-names></name><name><surname>Cuppen</surname> <given-names>E</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Sawyers</surname> <given-names>CL</given-names></name><name><surname>Clevers</surname> <given-names>HC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Identification of multipotent luminal progenitor cells in human prostate organoid cultures</article-title><source>Cell</source><volume>159</volume><fpage>163</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.08.017</pub-id><pub-id pub-id-type="pmid">25201529</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>KC</given-names></name><name><surname>Lee Kraus</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Nuclear receptors, coactivators and chromatin: new approaches, new insights</article-title><source>Trends in Endocrinology &amp; Metabolism</source><volume>12</volume><fpage>191</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1016/S1043-2760(01)00392-7</pub-id><pub-id pub-id-type="pmid">11397643</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leo</surname> <given-names>C</given-names></name><name><surname>Chen</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The SRC family of nuclear receptor coactivators</article-title><source>Gene</source><volume>245</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/S0378-1119(00)00024-X</pub-id><pub-id pub-id-type="pmid">10713439</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Machanick</surname> <given-names>P</given-names></name><name><surname>Bailey</surname> <given-names>TL</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>MEME-ChIP: motif analysis of large DNA datasets</article-title><source>Bioinformatics</source><volume>27</volume><fpage>1696</fpage><lpage>1697</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btr189</pub-id><pub-id pub-id-type="pmid">21486936</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohammed</surname> <given-names>H</given-names></name><name><surname>D'Santos</surname> <given-names>C</given-names></name><name><surname>Serandour</surname> <given-names>AA</given-names></name><name><surname>Ali</surname> <given-names>HR</given-names></name><name><surname>Brown</surname> <given-names>GD</given-names></name><name><surname>Atkins</surname> <given-names>A</given-names></name><name><surname>Rueda</surname> <given-names>OM</given-names></name><name><surname>Holmes</surname> <given-names>KA</given-names></name><name><surname>Theodorou</surname> <given-names>V</given-names></name><name><surname>Robinson</surname> <given-names>JL</given-names></name><name><surname>Zwart</surname> <given-names>W</given-names></name><name><surname>Saadi</surname> <given-names>A</given-names></name><name><surname>Ross-Innes</surname> <given-names>CS</given-names></name><name><surname>Chin</surname> <given-names>SF</given-names></name><name><surname>Menon</surname> <given-names>S</given-names></name><name><surname>Stingl</surname> <given-names>J</given-names></name><name><surname>Palmieri</surname> <given-names>C</given-names></name><name><surname>Caldas</surname> <given-names>C</given-names></name><name><surname>Carroll</surname> <given-names>JS</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor</article-title><source>Cell Reports</source><volume>3</volume><fpage>342</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2013.01.010</pub-id><pub-id pub-id-type="pmid">23403292</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mu</surname> <given-names>P</given-names></name><name><surname>Zhang</surname> <given-names>Z</given-names></name><name><surname>Benelli</surname> <given-names>M</given-names></name><name><surname>Karthaus</surname> <given-names>WR</given-names></name><name><surname>Hoover</surname> <given-names>E</given-names></name><name><surname>Chen</surname> <given-names>CC</given-names></name><name><surname>Wongvipat</surname> <given-names>J</given-names></name><name><surname>Ku</surname> <given-names>SY</given-names></name><name><surname>Gao</surname> <given-names>D</given-names></name><name><surname>Cao</surname> <given-names>Z</given-names></name><name><surname>Shah</surname> <given-names>N</given-names></name><name><surname>Adams</surname> <given-names>EJ</given-names></name><name><surname>Abida</surname> <given-names>W</given-names></name><name><surname>Watson</surname> <given-names>PA</given-names></name><name><surname>Prandi</surname> <given-names>D</given-names></name><name><surname>Huang</surname> <given-names>CH</given-names></name><name><surname>de Stanchina</surname> <given-names>E</given-names></name><name><surname>Lowe</surname> <given-names>SW</given-names></name><name><surname>Ellis</surname> <given-names>L</given-names></name><name><surname>Beltran</surname> <given-names>H</given-names></name><name><surname>Rubin</surname> <given-names>MA</given-names></name><name><surname>Goodrich</surname> <given-names>DW</given-names></name><name><surname>Demichelis</surname> <given-names>F</given-names></name><name><surname>Sawyers</surname> <given-names>CL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer</article-title><source>Science</source><volume>355</volume><fpage>84</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1126/science.aah4307</pub-id><pub-id pub-id-type="pmid">28059768</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Podolak</surname> <given-names>J</given-names></name><name><surname>Eilers</surname> <given-names>K</given-names></name><name><surname>Newby</surname> <given-names>T</given-names></name><name><surname>Slottke</surname> <given-names>R</given-names></name><name><surname>Tucker</surname> <given-names>E</given-names></name><name><surname>Olson</surname> <given-names>SB</given-names></name><name><surname>Lue</surname> <given-names>HW</given-names></name><name><surname>Youngren</surname> <given-names>J</given-names></name><name><surname>Aggarwal</surname> <given-names>R</given-names></name><name><surname>Small</surname> <given-names>EJ</given-names></name><name><surname>Graff</surname> <given-names>JN</given-names></name><name><surname>Alumkal</surname> <given-names>JJ</given-names></name><name><surname>Beer</surname> <given-names>TM</given-names></name><name><surname>Thomas</surname> <given-names>GV</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer</article-title><source>Oncotarget</source><volume>8</volume><fpage>71447</fpage><lpage>71455</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.16169</pub-id><pub-id pub-id-type="pmid">29069718</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pomerantz</surname> <given-names>MM</given-names></name><name><surname>Li</surname> <given-names>F</given-names></name><name><surname>Takeda</surname> <given-names>DY</given-names></name><name><surname>Lenci</surname> <given-names>R</given-names></name><name><surname>Chonkar</surname> <given-names>A</given-names></name><name><surname>Chabot</surname> <given-names>M</given-names></name><name><surname>Cejas</surname> <given-names>P</given-names></name><name><surname>Vazquez</surname> <given-names>F</given-names></name><name><surname>Cook</surname> <given-names>J</given-names></name><name><surname>Shivdasani</surname> <given-names>RA</given-names></name><name><surname>Bowden</surname> <given-names>M</given-names></name><name><surname>Lis</surname> <given-names>R</given-names></name><name><surname>Hahn</surname> <given-names>WC</given-names></name><name><surname>Kantoff</surname> <given-names>PW</given-names></name><name><surname>Brown</surname> <given-names>M</given-names></name><name><surname>Loda</surname> <given-names>M</given-names></name><name><surname>Long</surname> <given-names>HW</given-names></name><name><surname>Freedman</surname> <given-names>ML</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis</article-title><source>Nature Genetics</source><volume>47</volume><fpage>1346</fpage><lpage>1351</lpage><pub-id pub-id-type="doi">10.1038/ng.3419</pub-id><pub-id pub-id-type="pmid">26457646</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname> <given-names>J</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Laffin</surname> <given-names>B</given-names></name><name><surname>Chen</surname> <given-names>X</given-names></name><name><surname>Choy</surname> <given-names>G</given-names></name><name><surname>Jeter</surname> <given-names>CR</given-names></name><name><surname>Calhoun-Davis</surname> <given-names>T</given-names></name><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Palapattu</surname> <given-names>GS</given-names></name><name><surname>Pang</surname> <given-names>S</given-names></name><name><surname>Lin</surname> <given-names>K</given-names></name><name><surname>Huang</surname> <given-names>J</given-names></name><name><surname>Ivanov</surname> <given-names>I</given-names></name><name><surname>Li</surname> <given-names>W</given-names></name><name><surname>Suraneni</surname> <given-names>MV</given-names></name><name><surname>Tang</surname> <given-names>DG</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration</article-title><source>Cell Stem Cell</source><volume>10</volume><fpage>556</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2012.03.009</pub-id><pub-id pub-id-type="pmid">22560078</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rae</surname> <given-names>JM</given-names></name><name><surname>Johnson</surname> <given-names>MD</given-names></name><name><surname>Scheys</surname> <given-names>JO</given-names></name><name><surname>Cordero</surname> <given-names>KE</given-names></name><name><surname>Larios</surname> <given-names>JM</given-names></name><name><surname>Lippman</surname> <given-names>ME</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>GREB 1 is a critical regulator of hormone dependent breast cancer growth</article-title><source>Breast Cancer Research and Treatment</source><volume>92</volume><fpage>141</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1007/s10549-005-1483-4</pub-id><pub-id pub-id-type="pmid">15986123</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname> <given-names>D</given-names></name><name><surname>Van Allen</surname> <given-names>EM</given-names></name><name><surname>Wu</surname> <given-names>YM</given-names></name><name><surname>Schultz</surname> <given-names>N</given-names></name><name><surname>Lonigro</surname> <given-names>RJ</given-names></name><name><surname>Mosquera</surname> <given-names>JM</given-names></name><name><surname>Montgomery</surname> <given-names>B</given-names></name><name><surname>Taplin</surname> <given-names>ME</given-names></name><name><surname>Pritchard</surname> <given-names>CC</given-names></name><name><surname>Attard</surname> <given-names>G</given-names></name><name><surname>Beltran</surname> <given-names>H</given-names></name><name><surname>Abida</surname> <given-names>W</given-names></name><name><surname>Bradley</surname> <given-names>RK</given-names></name><name><surname>Vinson</surname> <given-names>J</given-names></name><name><surname>Cao</surname> <given-names>X</given-names></name><name><surname>Vats</surname> <given-names>P</given-names></name><name><surname>Kunju</surname> <given-names>LP</given-names></name><name><surname>Hussain</surname> <given-names>M</given-names></name><name><surname>Feng</surname> <given-names>FY</given-names></name><name><surname>Tomlins</surname> <given-names>SA</given-names></name><name><surname>Cooney</surname> <given-names>KA</given-names></name><name><surname>Smith</surname> <given-names>DC</given-names></name><name><surname>Brennan</surname> <given-names>C</given-names></name><name><surname>Siddiqui</surname> <given-names>J</given-names></name><name><surname>Mehra</surname> <given-names>R</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Rathkopf</surname> <given-names>DE</given-names></name><name><surname>Morris</surname> <given-names>MJ</given-names></name><name><surname>Solomon</surname> <given-names>SB</given-names></name><name><surname>Durack</surname> <given-names>JC</given-names></name><name><surname>Reuter</surname> <given-names>VE</given-names></name><name><surname>Gopalan</surname> <given-names>A</given-names></name><name><surname>Gao</surname> <given-names>J</given-names></name><name><surname>Loda</surname> <given-names>M</given-names></name><name><surname>Lis</surname> <given-names>RT</given-names></name><name><surname>Bowden</surname> <given-names>M</given-names></name><name><surname>Balk</surname> <given-names>SP</given-names></name><name><surname>Gaviola</surname> <given-names>G</given-names></name><name><surname>Sougnez</surname> <given-names>C</given-names></name><name><surname>Gupta</surname> <given-names>M</given-names></name><name><surname>Yu</surname> <given-names>EY</given-names></name><name><surname>Mostaghel</surname> <given-names>EA</given-names></name><name><surname>Cheng</surname> <given-names>HH</given-names></name><name><surname>Mulcahy</surname> <given-names>H</given-names></name><name><surname>True</surname> <given-names>LD</given-names></name><name><surname>Plymate</surname> <given-names>SR</given-names></name><name><surname>Dvinge</surname> <given-names>H</given-names></name><name><surname>Ferraldeschi</surname> <given-names>R</given-names></name><name><surname>Flohr</surname> <given-names>P</given-names></name><name><surname>Miranda</surname> <given-names>S</given-names></name><name><surname>Zafeiriou</surname> <given-names>Z</given-names></name><name><surname>Tunariu</surname> <given-names>N</given-names></name><name><surname>Mateo</surname> <given-names>J</given-names></name><name><surname>Perez-Lopez</surname> <given-names>R</given-names></name><name><surname>Demichelis</surname> <given-names>F</given-names></name><name><surname>Robinson</surname> <given-names>BD</given-names></name><name><surname>Schiffman</surname> <given-names>M</given-names></name><name><surname>Nanus</surname> <given-names>DM</given-names></name><name><surname>Tagawa</surname> <given-names>ST</given-names></name><name><surname>Sigaras</surname> <given-names>A</given-names></name><name><surname>Eng</surname> <given-names>KW</given-names></name><name><surname>Elemento</surname> <given-names>O</given-names></name><name><surname>Sboner</surname> <given-names>A</given-names></name><name><surname>Heath</surname> <given-names>EI</given-names></name><name><surname>Scher</surname> <given-names>HI</given-names></name><name><surname>Pienta</surname> <given-names>KJ</given-names></name><name><surname>Kantoff</surname> <given-names>P</given-names></name><name><surname>de Bono</surname> <given-names>JS</given-names></name><name><surname>Rubin</surname> <given-names>MA</given-names></name><name><surname>Nelson</surname> <given-names>PS</given-names></name><name><surname>Garraway</surname> <given-names>LA</given-names></name><name><surname>Sawyers</surname> <given-names>CL</given-names></name><name><surname>Chinnaiyan</surname> <given-names>AM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Integrative clinical genomics of advanced prostate cancer</article-title><source>Cell</source><volume>161</volume><fpage>1215</fpage><lpage>1228</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.05.001</pub-id><pub-id pub-id-type="pmid">26000489</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rockowitz</surname> <given-names>S</given-names></name><name><surname>Zheng</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Significant expansion of the REST/NRSF cistrome in human versus mouse embryonic stem cells: potential implications for neural development</article-title><source>Nucleic Acids Research</source><volume>43</volume><fpage>5730</fpage><lpage>5743</lpage><pub-id pub-id-type="doi">10.1093/nar/gkv514</pub-id><pub-id pub-id-type="pmid">25990720</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruizeveld de Winter</surname> <given-names>JA</given-names></name><name><surname>Janssen</surname> <given-names>PJ</given-names></name><name><surname>Sleddens</surname> <given-names>HM</given-names></name><name><surname>Verleun-Mooijman</surname> <given-names>MC</given-names></name><name><surname>Trapman</surname> <given-names>J</given-names></name><name><surname>Brinkmann</surname> <given-names>AO</given-names></name><name><surname>Santerse</surname> <given-names>AB</given-names></name><name><surname>Schröder</surname> <given-names>FH</given-names></name><name><surname>van der Kwast</surname> <given-names>TH</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer</article-title><source>The American Journal of Pathology</source><volume>144</volume><fpage>735</fpage><lpage>746</lpage><pub-id pub-id-type="pmid">7512791</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname> <given-names>N</given-names></name><name><surname>Wang</surname> <given-names>P</given-names></name><name><surname>Wongvipat</surname> <given-names>J</given-names></name><name><surname>Karthaus</surname> <given-names>WR</given-names></name><name><surname>Abida</surname> <given-names>W</given-names></name><name><surname>Armenia</surname> <given-names>J</given-names></name><name><surname>Rockowitz</surname> <given-names>S</given-names></name><name><surname>Drier</surname> <given-names>Y</given-names></name><name><surname>Bernstein</surname> <given-names>BE</given-names></name><name><surname>Long</surname> <given-names>HW</given-names></name><name><surname>Freedman</surname> <given-names>ML</given-names></name><name><surname>Arora</surname> <given-names>VK</given-names></name><name><surname>Zheng</surname> <given-names>D</given-names></name><name><surname>Sawyers</surname> <given-names>CL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer</article-title><source>eLife</source><volume>6</volume><elocation-id>e27861</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.27861</pub-id><pub-id pub-id-type="pmid">28891793</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname> <given-names>MM</given-names></name><name><surname>Abate-Shen</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Molecular genetics of prostate cancer: new prospects for old challenges</article-title><source>Genes &amp; Development</source><volume>24</volume><fpage>1967</fpage><lpage>2000</lpage><pub-id pub-id-type="doi">10.1101/gad.1965810</pub-id><pub-id pub-id-type="pmid">20844012</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snoek</surname> <given-names>R</given-names></name><name><surname>Bruchovsky</surname> <given-names>N</given-names></name><name><surname>Kasper</surname> <given-names>S</given-names></name><name><surname>Matusik</surname> <given-names>RJ</given-names></name><name><surname>Gleave</surname> <given-names>M</given-names></name><name><surname>Sato</surname> <given-names>N</given-names></name><name><surname>Mawji</surname> <given-names>NR</given-names></name><name><surname>Rennie</surname> <given-names>PS</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Differential transactivation by the androgen receptor in prostate cancer cells</article-title><source>The Prostate</source><volume>36</volume><fpage>256</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0045(19980901)36:4&lt;256::AID-PROS7&gt;3.0.CO;2-D</pub-id><pub-id pub-id-type="pmid">9719026</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takayama</surname> <given-names>K</given-names></name><name><surname>Suzuki</surname> <given-names>T</given-names></name><name><surname>Tsutsumi</surname> <given-names>S</given-names></name><name><surname>Fujimura</surname> <given-names>T</given-names></name><name><surname>Takahashi</surname> <given-names>S</given-names></name><name><surname>Homma</surname> <given-names>Y</given-names></name><name><surname>Urano</surname> <given-names>T</given-names></name><name><surname>Aburatani</surname> <given-names>H</given-names></name><name><surname>Inoue</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Integrative analysis of FOXP1 function reveals a tumor-suppressive effect in prostate cancer</article-title><source>Molecular Endocrinology</source><volume>28</volume><fpage>2012</fpage><lpage>2024</lpage><pub-id pub-id-type="doi">10.1210/me.2014-1171</pub-id><pub-id pub-id-type="pmid">25329375</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname> <given-names>BS</given-names></name><name><surname>Schultz</surname> <given-names>N</given-names></name><name><surname>Hieronymus</surname> <given-names>H</given-names></name><name><surname>Gopalan</surname> <given-names>A</given-names></name><name><surname>Xiao</surname> <given-names>Y</given-names></name><name><surname>Carver</surname> <given-names>BS</given-names></name><name><surname>Arora</surname> <given-names>VK</given-names></name><name><surname>Kaushik</surname> <given-names>P</given-names></name><name><surname>Cerami</surname> <given-names>E</given-names></name><name><surname>Reva</surname> <given-names>B</given-names></name><name><surname>Antipin</surname> <given-names>Y</given-names></name><name><surname>Mitsiades</surname> <given-names>N</given-names></name><name><surname>Landers</surname> <given-names>T</given-names></name><name><surname>Dolgalev</surname> <given-names>I</given-names></name><name><surname>Major</surname> <given-names>JE</given-names></name><name><surname>Wilson</surname> <given-names>M</given-names></name><name><surname>Socci</surname> <given-names>ND</given-names></name><name><surname>Lash</surname> <given-names>AE</given-names></name><name><surname>Heguy</surname> <given-names>A</given-names></name><name><surname>Eastham</surname> <given-names>JA</given-names></name><name><surname>Scher</surname> <given-names>HI</given-names></name><name><surname>Reuter</surname> <given-names>VE</given-names></name><name><surname>Scardino</surname> <given-names>PT</given-names></name><name><surname>Sander</surname> <given-names>C</given-names></name><name><surname>Sawyers</surname> <given-names>CL</given-names></name><name><surname>Gerald</surname> <given-names>WL</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Integrative genomic profiling of human prostate cancer</article-title><source>Cancer Cell</source><volume>18</volume><fpage>11</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2010.05.026</pub-id><pub-id pub-id-type="pmid">20579941</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veldscholte</surname> <given-names>J</given-names></name><name><surname>Berrevoets</surname> <given-names>CA</given-names></name><name><surname>Ris-Stalpers</surname> <given-names>C</given-names></name><name><surname>Kuiper</surname> <given-names>GG</given-names></name><name><surname>Jenster</surname> <given-names>G</given-names></name><name><surname>Trapman</surname> <given-names>J</given-names></name><name><surname>Brinkmann</surname> <given-names>AO</given-names></name><name><surname>Mulder</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens</article-title><source>The Journal of Steroid Biochemistry and Molecular Biology</source><volume>41</volume><fpage>665</fpage><lpage>669</lpage><pub-id pub-id-type="doi">10.1016/0960-0760(92)90401-4</pub-id><pub-id pub-id-type="pmid">1562539</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Q</given-names></name><name><surname>Carroll</surname> <given-names>JS</given-names></name><name><surname>Brown</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking</article-title><source>Molecular Cell</source><volume>19</volume><fpage>631</fpage><lpage>642</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2005.07.018</pub-id><pub-id pub-id-type="pmid">16137620</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Wang</surname> <given-names>S</given-names></name><name><surname>Li</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>RSeQC: quality control of RNA-seq experiments</article-title><source>Bioinformatics</source><volume>28</volume><fpage>2184</fpage><lpage>2185</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts356</pub-id><pub-id pub-id-type="pmid">22743226</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>T</given-names></name><name><surname>Wei</surname> <given-names>JJ</given-names></name><name><surname>Sabatini</surname> <given-names>DM</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Genetic screens in human cells using the CRISPR-Cas9 system</article-title><source>Science</source><volume>343</volume><fpage>80</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1126/science.1246981</pub-id><pub-id pub-id-type="pmid">24336569</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watson</surname> <given-names>PA</given-names></name><name><surname>Arora</surname> <given-names>VK</given-names></name><name><surname>Sawyers</surname> <given-names>CL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer</article-title><source>Nature Reviews Cancer</source><volume>15</volume><fpage>701</fpage><lpage>711</lpage><pub-id pub-id-type="doi">10.1038/nrc4016</pub-id><pub-id pub-id-type="pmid">26563462</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshihara</surname> <given-names>K</given-names></name><name><surname>Shahmoradgoli</surname> <given-names>M</given-names></name><name><surname>Martínez</surname> <given-names>E</given-names></name><name><surname>Vegesna</surname> <given-names>R</given-names></name><name><surname>Kim</surname> <given-names>H</given-names></name><name><surname>Torres-Garcia</surname> <given-names>W</given-names></name><name><surname>Treviño</surname> <given-names>V</given-names></name><name><surname>Shen</surname> <given-names>H</given-names></name><name><surname>Laird</surname> <given-names>PW</given-names></name><name><surname>Levine</surname> <given-names>DA</given-names></name><name><surname>Carter</surname> <given-names>SL</given-names></name><name><surname>Getz</surname> <given-names>G</given-names></name><name><surname>Stemke-Hale</surname> <given-names>K</given-names></name><name><surname>Mills</surname> <given-names>GB</given-names></name><name><surname>Verhaak</surname> <given-names>RG</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Inferring tumour purity and stromal and immune cell admixture from expression data</article-title><source>Nature Communications</source><volume>4</volume><elocation-id>2612</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms3612</pub-id><pub-id pub-id-type="pmid">24113773</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Younesy</surname> <given-names>H</given-names></name><name><surname>Nielsen</surname> <given-names>CB</given-names></name><name><surname>Lorincz</surname> <given-names>MC</given-names></name><name><surname>Jones</surname> <given-names>SJ</given-names></name><name><surname>Karimi</surname> <given-names>MM</given-names></name><name><surname>Möller</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>ChAsE: chromatin analysis and exploration tool</article-title><source>Bioinformatics</source><volume>32</volume><fpage>3324</fpage><lpage>3326</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btw382</pub-id><pub-id pub-id-type="pmid">27378294</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.41913.035</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Tannock</surname><given-names>Ian</given-names></name><role>Reviewing Editor</role><aff><institution>Princess Margaret Cancer Centre</institution><country>Canada</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your article &quot;<italic>GREB1</italic> amplifies androgen receptor output in prostate cancer and contributes to antiandrogen resistance&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Sean Morrison as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Gert Attard (Reviewer #2); Myles Brown (Reviewer #3).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>The finding that <italic>GREB1</italic> amplifies androgen output in prostate cancer cell lines and does so by 2 mechanisms including enhancing AR binding and co-activator activity has implications for resistance of PC to enzalutamide and other AR targeting agents.</p><p>Essential revisions:</p><p>1) Statistical tests/results should be added to the figure panels and should be more clearly specified throughout the text and in the figures.</p><p>2) The authors use both LNCAP and LNCaP with stably over-expressing AR (for xenograft work and based on previous studies). The use of these models needs to be clarified in the figures (especially Figure 1) as it is currently hard to follow.</p><p>3) Figure 2F. Please indicate what AR score was used and what is the y axis? Ideally the distribution for <italic>GREB1</italic> expression across the full data set should be shown and the ARsig-hi and ARsig-lo marked on this?</p><p>4) Regarding Figure 4H, in the Discussion the authors conclude &quot;we show that elevated levels of <italic>GREB1</italic> in CRPC tumors correlate with a poor clinical response to enzalutamide, analogous to the prognostic impact of AR gene amplification&quot;. This is inaccurate. The authors show increased expression in tumors collected at progression vs. baseline. Have these been controlled for tumor fraction and other potential biases?</p><p>5) There are a few grammatical errors in the figure legends, such as in that of Figure 4H. Please correct.</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.41913.036</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) Statistical tests/results should be added to the figure panels and should be more clearly specified throughout the text and in the figures.</p></disp-quote><p>Thank you for noting this. We have added statistical results in revised Figure 1D, 1H, 1I, Figure 1—figure supplement 1B, 1E, Figure 1—figure supplement 3B, Figure 2E, Figure 2—figure supplement 1A, Figure 3A, 3B, 3E, 3F, 3G, 3H, Figure 3—figure supplement 1A, 1B, Figure 3—figure supplement 2A, 2C, Figure 3—figure supplement 3A, 3B, 3D, 3E, Figure 4A, 4C, Figure 4—figure supplement 1A and 1E. We have also edited the figure legends to specify the statistical analysis used in each figure.</p><disp-quote content-type="editor-comment"><p>2) The authors use both LNCAP and LNCaP with stably over-expressing AR (for xenograft work and based on previous studies). The use of these models needs to be clarified in the figures (especially Figure 1) as it is currently hard to follow.</p></disp-quote><p>We appreciate the feedback and have specified the cell lines throughout in the figures and figure legends.</p><disp-quote content-type="editor-comment"><p>3) Figure 2F. Please indicate what AR score was used and what is the y axis? Ideally the distribution for GREB1 expression across the full data set should be shown and the ARsig-hi and ARsig-lo marked on this?</p></disp-quote><p>We used the same AR score as in the TCGA study (Cancer Genome Atlas Research, 2015; Hieronymus et al., 2006). The original Figure 2F did not have y-axis. As suggested by the reviewers, we’ve combined the original Figure 2F and 2G and now show the distribution of <italic>GREB1, GHRHR</italic> and <italic>KLF8</italic> expression across the 333 TCGA tumors. We have marked ARsig-lo and ARsig-hi cases to show that the expression of <italic>GREB1</italic>, but not <italic>GHRHR</italic> or <italic>KLF8</italic>, is increased in ARsig-hi cases (new Figure 2F). We have also analyzed the Pearson’s correlation (<italic>r</italic>) between RNA level of each gene and AR score across the TCGA tumors and observed that only <italic>GREB1</italic> expression shows significantly positive correlation with AR score (<italic>r</italic>=0.55, P&lt;0.0001).</p><disp-quote content-type="editor-comment"><p>4) Regarding Figure 4H, in the Discussion the authors conclude &quot;we show that elevated levels of GREB1 in CRPC tumors correlate with a poor clinical response to enzalutamide, analogous to the prognostic impact of AR gene amplification&quot;. This is inaccurate. The authors show increased expression in tumors collected at progression vs baseline. Have these been controlled for tumor fraction and other potential biases?</p></disp-quote><p>We thank the reviewers for pointing this out and have edited the Discussion to clarify this. We did not intend to claim that <italic>GREB1</italic> is a prognostic biomarker (although future work may address this possibility).</p><p>Regarding tumor purity, we have analyzed tumor content and stromal signature scores of patient samples as described previously (Carter et al., 2012; Shah et al., 2017; Yoshihara et al., 2013). We observed no significant change in both tumor purity content and stromal signature score between pre- vs. post-enzalutamide setting, suggesting that increased <italic>GREB1</italic> expression is not caused by different tumor content between samples. These analyses are presented in new Figure 4—figure supplement 1F.</p><disp-quote content-type="editor-comment"><p>5) There are a few grammatical errors in the figure legends, such as in that of Figure 4H. Please correct.</p></disp-quote><p>We appreciate the feedback and have corrected grammatical errors in figure legends.</p></body></sub-article></article>